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Introduction 
 
 
 I. INTRODUCTION 
1. PREVALENCE OF TYPE 2 DIABETES MELLITUS 
1.1 Global scenario  
                        Diabetes is a high incidence, chronic, globally, occurring disease that seriously 
trailing ground quality of the life1. Even today type 2 diabetes is one of the principal health 
care problems worldwide, and its scale is forecast to grow in the near future2. There is likely 
one person undiagnosed for every three persons presently diagnosed with the disease3.The 
global increase in dominance of diabetes is due to population growth, aging, urbanization and 
increase of obesity and physical inactivity4.  
                        According to recent estimates, approximately 285 million people worldwide 
(6.6%) in 20-79 years age fraction have diabetes in 2010 and by 2030, 438 million people 
7.8% of adult inhabitants is expected to have diabetes4. The total number of individuals with 
diabetes worldwide is anticipated to rise from about 170 million (2.8%) in 2000 to about 370 
million (4.4%) in 20305, 6. At both time points of 2010 and 2030 the three countries with 
prevalent number of people with diabetes are India, china and US respectively4. Although no 
nation or cultures are off the hook from this devastating disease, developing countries will 
account for 150% of the increase7. Type 2 diabetes is the commonest form of diabetes 
constituting 90% of diabetic populace in any country8, 9.  
Diabetes shortens the life bated breath by about 15 years 10. Diabetes mellitus 
is the foremost cause of blindness in adults aged 20 to 74 years and leading contributor to 
advance of end stage renal disease3. It accounts for around 82,000 lower extremity 
amputations annually3. Approximately 4 million deaths each year are caused by diabetes 
related complications, adding up an astounding 9% of deaths worldwide7. Annual deaths 
attributable to diabetes are perhaps as high as 3 million (54% of deaths which is predicted to 
rise by 65% by 2030) with more than 80% occur in developing countries 11. Macro vascular 
complications are the most widespread and are responsible for almost 70% of the deaths in 
chronic kidney disease exceeded 20% per year in patients with diabetes and that cardio 
vascular disease is in charge for two third of deaths amongdiabetic patients with end stage 
renal disease 3, 12, 13. Low prevalence of peripheral vascular disease was verified in Indian 
patient as 4.0% 9.  
                        Currently it is calculated that the population with diabetes consumes 4-14% of 
the global health expenses in western countries and that a patient with diabetes consumes 2-6 
more direct resources than individuals of similar age and gender with other chronic diseases2. 
Health expenditure on diabetes is to account for 11.6% of total health care outflow in the 
world in 20104. It has been estimated that diabetic patient consumes at least more or less 5-
6% of health care expenditures in developed countries and that a diabetic patient consumes 
more resources than does a non-diabetic patient1. Estimated global health care expenditures 
to treat and prevent diabetes and its complications are likely to total at least 376 billion USD 
in 2010, by 2030, the number is predictable to exceed some USD 490 billion4. 
1.2 Indian scenario 
                        Diabetes mellitus is rapidly rising as major health care challenge in India, 
especially in urban areas14. Although poor Indians are currently at lower risk than affluent 
Indians, the rapid spread of fast food exposes even urban Indian slum dwellers to the peril of 
diabetes15. More over there is uniformly large pool of persons with impaired glucose 
tolerance (IGT) many of whom will develop type 2 diabetes in future14. The lack of ample 
facilities and financial capacity indirectly worsens long term prognosis8. The prevailing 
poverty, unawareness, illiteracy and poor health consciousness further adds to the problem8, 
14.  
                        The WHO recently revised its estimates of the persons with diabetes in India 
in 2000 as 31.7 million, the number is prone to increase to 79.4 million in 2030 14, 16. 
Prevalence of impaired glucose tolerance was also elevated as 14.0%9. A countrywide survey 
of diabetes conducted in six major cities in India in year 2000 showed that the prevalence of 
diabetes in urban adults was 12.1% 9. Crude estimate suggest that type 2 diabetes 
pervasiveness in rural areas is much lower (approximate ly 25-50%) than in urban areas is 
rapidly catching up with the urban areas17. Prevalence is only 0.7% for non-obese physically 
active rural Indians, but it reaches 11% for obese, deskbound and urban Indians4.  The exact 
age of onset of T2DM subjects is not clear because many folks in this population do not 
undergo regular checkup until symptoms appear; thus, diabetes may remain undiagnosed for 
4 to 7 years18. Studies in India point out that more than 50% of people with diabetes have 
poor glycemic control (HbAIc >8%), uncontrolled hypertension, dyslipidemia and a large 
proportion have diabetic vascular complications4. It is found faintly more in men with age 
<60 years and in women at older age16. The ages of inception in India has been shifting 
towards even younger people within the past decade and are more likely to fall in prey to 
complications ranging from heart attack and strokes to blindness and sexual dysfunction15, 19. 
                        In urban India, there are spacious social and economic disparities9. Free health 
care facilities are available for the economically backward classes, but due to low level of 
education and job-related problems, the facilities are not always used9. Management of 
diabetes involves finest glucose control which can be achieved through strict adherence to 
medications, diet and exercise which in turn minimizes long term complications16. Emerging 
therapies are designed to offer an option to standard therapies, which may get better glycemic 
control and help reduce incidence or the severity of complications and hence, the cost of type 
2 diabetes20. 
                        Diabetes being a lifelong disorder is an expensive ailment for a very large 
fraction of subjects in developing societies9. Considering a rather low estimate of 
approximately 20 million diabetic patients in India, the annual projected cost could be Rs. 
90,200/- million (USD 2.2 billion) for diabetic health care9. In Indian perspective the 
financial burden is often shared by relatives of the patient9. The currency spent was from 
family‟s financial resources9. Studies in India estimate that for a low income Indian family an 
adult with diabetes, as much as 25% of family income may be committed to diabetes care and 
India will suffer cumulative gross domestic product loss of 16.7 % over 10 year period11, 21. 
Many socioeconomic factors and health care delivery related issues impact the outcome of 
diabetes and therefore the costs and vice versa 14. Persons with diabetes use higher health care 
funds and excess cost are related to higher cost to treat complications 14. In India, direct 
expenditure correlated to diabetes care is presently Rs 10,000 crores which is likely to scale 
up to Rs 1, 25,000 crores by 202516. 
                        In view of towering prevalence of diabetes and the vascular complications in 
Indians, emphasis must be given on primary prevention of diabetes as major combat the 
disorder9. Serious efforts should be made to spotlight and upscale activities on health 
promotion and prevention of diabetes which could provide a more cost effective solution to 
this condition with huge and increasing economic loss11. Overall diabetes care in India leaves 
much to be preferred 5. 
2. DIABETES MELLITUS 
                        Diabetes is a group of carbohydrate metabolic disorder characterized by 
resistance to the action of insulin, inadequate insulin secretion, or both. The medical 
manifestation of these disorders is hyperglycemia 3, 22. Very high glucose levels can cause 
fatigue, dehydration, and even death. Long standing diabetes is associated with increased 
incidence of micro vascular and macro vascular disease9. As the disease progresses tissue or 
vascular damage ensues leading to harsh complications such as retinopathy, nephropathy, 
neuropathy, cardiovascular disease, and foot ulceration 22, 23. Long term clinical follow up 
studies have shown that improvements in glycemic control, Blood Pressure, and Cholesterol 
level lead to fewer micro & macro vascular complications and progress health outcomes24.
  
2.1 Epidemiology 
                        Diabetes is a chronic extensive devastating metabolic disease which can affect 
every organ in the body and is an important cause of premature death and disability 10, 13, 19. 
Diabetes is prevailed in parallel proportion in both men and women 16. It is the most leading 
reason of morbidity and mortality in most developed countries 10, 13. Poor management leads 
to several complications and end organ damage that finally impairs the health related quality 
of life in individuals 16. Long term thorough glycemic control is essential to manage and 
prevent complications 10, 19. People with diabetes are at amplified risk of developing long 
term complications related to micro vascular (ex: retinopathy, neuropathy, nephropathy, foot 
ulcer) and macro vascular (ex: heart, cerebral and peripheral vascular diseases) 12, 13, when 
compared with non diabetic patient in the same age group 1. Typical type 1 diabetes accounts 
for 5-10% of all cases of diabetes and is an auto immune disorder mounting in childhood or 
early adulthood although some latent forms do occurs 3.  Type 2 diabetes is a chronic disease 
characterized by hyperglycemia and dyslipidemia due to underlying insulin resistance 13.  
2.1.1 Risk factors leading to Diabetes Mellitus. 
 A genetic predisposition (i.e parents or siblings with diabetes) 3, 15. 
 Lifestyle factors, especially those of so called  westernized way of life, characterized 
by high calorie intake and little exercise 15.  
 Central obesity (i.e ≥ 20% over ideal body weight or Body mass index ≥ 25 kg/m2) 3, 
10.   
 Habitual physical inactivity 3. 
 Race or ethinicity (previously identified impaired glucose tolerance or impaired 
fasting glucose) 3. 
 Hypertension (≥140/90 mm Hg in adults) 3. 
 HDL cholesterol ≤ 35 mg/dL and/or triglycerides ≥ 250mg/dL3.  
 History of gestational diabetes or delivery of a baby weighing >4 Kg 3.  
 History of vascular disease 3.  
 Presence of acanthosisnigricans; and polycystic ovary disease 3.   
2.2 Classification of Diabetes 
DM may be categorized into numerous types but the two major types are:-  
Type 1 Diabetes(insulin-dependent diabetes mellitus (IDDM) / Juvenile-onset diabetes): This 
form of the disease has an auto- immune basis of destruction of β cells of the pancreas in most 
cases, and generally occurs in children, adolescents and it can occur at any age 3, 22. Itis 
present with little or no endogenous insulin secretory capacity and hence requires exogenous 
insulin therapy for survival. The coupled hypoinsulinaemia and hyperglucagonaemia put such 
patients at risk of ketosis and ketoacidosis 22. 
Type 2 Diabetes(non- insulin-dependent diabetes mellitus (NIDDM) / maturity onset 
diabetes): This disease classically develops in later life 22. Insulin secretion may appear 
normal or even excessive but it is in short supply to compensate for insulin resistance, due to 
cluster of abnormalities like obesity, hypertension, dyslipidemia, and elevated plasminogen 
activator inhibitor type 1 (PAI-1) levels collectively referred as the insulin 
resistancesyndrome or metabolic syndrome 3, 22. Type 2 diabetes has a strong genetic 
predisposition and patients with type 2 diabetes are at augmented risk of developing 
macrovascular complications 3.   
Type I DM 25 Type II DM25 
Formerly called insulin-dependent 
(IDDM), juvenile-onset, or brittle DM25 
Formerly called non–insulin-dependent 
[NIDDM] or adult-onset DM25 
Represents 5%–10% of diabetic 
patients25 
Represents 90%–95% of diabetic 
patients25 
Autoimmune disease in which 
pancreatic beta islet cell are targets of 
destruction25 
Varies from predominantly insulin 
resistance in muscle and fat with relative 
deficiency to predominantly insulin 
secretory defect with insulin resistance. 
Relative rather than absolute insulin 
deficiency25 
Autoantibodies are present in 85%–90% 
of cases. Other autoimmune disorders 
may be present (e.g., Graves disease, 
Hashimoto thyroiditis, Addison disease, 
pernicious anemia) 25 
Associated with dyslipidemia, obesity (in 
80%–90% of cases), increasing age, 
hypertension, family history25 
Insulin secretion is virtually absent 
Plasma C-peptide is low or undetectable 
in contrast to Type 225 
Plasma insulin may be normal or 
increased but is expected to be higher 
relative to blood glucose concentration25 
Ketosis prone25 Ketosis occurs with stress (e.g., 
infection), but seldom spontaneously25 
 
 
2.3 Pathogenesis 
                        The islets of Langerhans are the endocrine component of the pancreas 26. 
Insulin is synthesized in the pancreatic β- cells, initially as a polypeptide precursor, pre-
proinsulin 26. The latter is rapidly transformed in the pancreas to proinsulin 26. This forms 
equal amounts of insulin and C-peptide through removal of four amino acid residues 26. 
Insulin consists of 51 amino acids in two chains (A chain contains 21 amino acids and B 
chain contains 30), linked by two disulfide bridges 26. In islets, insulin and C-peptide are 
crammed into granules. Insulin associates impulsively into a hexamer containing two zinc 
ions and calcium ions 26.Glucose is the major stimulant to insulin release 26. The response is 
triggered both by the intake of nutrients and the discharge of gastrointestinal peptide 
hormones 26.  
                        Once released from the pancreas, insulin enters the portal circulation 26. In 
basal state, insulin secretion is at a rate of approximately 1 unit per hour 26. Total daily 
secretion is approximately 40 units 26. Insulin circulates free as a monomer, has a half- life of 
4-5 minutes and is principally metabolized by the liver and kidneys 26. In kidneys, insulin is 
filtered by the glomeruli and reabsorbed by the tubules and degraded 26. Peripheral tissues 
such as muscle and fat also degrade insulin but this is of minor quantitative significance 26. 
The interaction of insulin with the receptor on the cell of surface sets off a chain of 
messengers within the cell 26. This opens up transport processes for glucose, amino acids, and 
electrolytes 26. 
Type 1 DM is characterized by an utter deficiency of pancreatic β-cell 
function resulting of an immune-mediated destruction of pancreatic β cells mediated by 
macrophages and T- lymphocytes with circulating auto-antibodies to various β-cell antigens, 
but rare unknown or idiopathic processes can throw in 3. Destruction of pancreatic β-cell 
function causes hyperglycemia because of an absolute deficiency of both insulin and amylin 
3. Also glucose uptake is decreased in insulin- sensitive tissues, hence hyperglycemia ensues 
that leads to unrestrained hepatic glycogenolysis and gluconeogenesis with a ensuing increase 
in hepatic glucose output 26. Insulin lowers blood glucose by a variety of mechanisms 
including: stimulation of tissue glucose uptake, suppression of glucose production by the 
liver, and suppression of free fatty acid release from fat cells3. The suppression of free fatty 
acids plays an important role in glucose homeostasis3. Increased levels of free fatty acids 
inhibit the uptake of glucose by muscle and stimulate hepatic gluconeogenesis3. Amylin, a 
glucoregulatory peptide hormone cosecreted with insulin, plays a role in lowering blood 
glucose by slowing gastric emptying, suppressing glucagon output from pancreatic α cells, 
and increasing satiety 3. 
 In type II diabetes the process is usually less acute, since insulin production 
decreases over a sustained period of time 26. Glucagon, produced by pancreatic α cells, is 
secreted in the fasting state to oppose the action of insulin and stimulate hepatic glucose 
production 3. Thus, glucagon prevents hypoglycemia or restores normoglycemia if 
hypoglycemia has occurred 3. The resultant hyperinsulinemia (1) suppresses hepatic glucose 
production and (2) stimulates glucose uptake by peripheral tissues 3.Hyperinsulinnemia is 
able to maintain glucose levels for a period of time but eventually β-cell function deteriorates 
and hyperglycemia ensues 26. If this cycle is not interrupted, type 2 diabetes develops 26. Type 
2diabetes is also associated with metabolic syndrome, which is a group of risk factors 
frequently found in those with type 2 diabetes, including insulin resistance, glucose 
intolerance, hyperinsulinnemia, hypertension, dyslipidemia, central obesity, artherosclerosis 
and increased levels of procoagulant factors, ex: plasminogen activator inhibitor-I and 
fibrinogen 26. Small increments in the plasma insulin concentration exert a potent antilipolytic 
effect, leading to a marked reduction in the plasma free fatty acid (FFA) level 3. The decline 
in plasma FFA concentration results in increased glucose uptake in muscle 3. Thus a decrease 
in the plasma FFA concentration lowers plasma glucose by both decreasing its production 
and enhancing the uptake in muscle 3.  
2.4 Pathophysiology 
Hepatic insulin resistance and hyperglucagonemia result in continued 
production of glucose by the liver, a shortened gastric emptying time can result in marked 
hyperglycemia 3. Increased insulin concentration, causes muscle glucose uptake. In lean type 
2 diabetic subjects, the onset of insulin action is delayed and the ability of insulin to stimulate 
leg glucose uptake is reduced3. Therefore the primary site of insulin resistance in type 2 
diabetic subjects resides in muscle tissue3. Insulin is a potent inhibitor of lipolysis, and 
restrains the release of FFAs from the adipocyte by inhibiting the hormone-sensitive lipase 
enzyme 3. Chronically elevated plasma FFA concentrations can lead to insulin resistance in 
muscle and liver and impair insulin secretion 3. Increased stores of triglycerides in muscle 
and liver and the increased fat content correlates closely with the presence of insulin 
resistance in these tissues 3.  
1.4.1. Cellular Mechanisms of Insulin Resistance 
2.4.1.1 Obesity and Insulin Resistance  
Abdominal fat is resistant to the anti- lipolytic effects of insulin, resulting in 
the release of excessive amounts of free fatty acids, which in turn lead to insulin resistance in 
the liver and muscles 26. The effect is an increase in gluconeogenesis in the liver and an 
inhibition of insulin-mediated glucose uptake in the muscle 26. These both result in increased 
levels of circulating glucose 26. Furthermore, excess fat itself may contribute to insulin 
resistance because when adipocytes become too large they are unable to store additional fat, 
resulting in fat storage in the muscles, liver and pancrease, causing insulin resistance in these 
organs 26. Adipose tissue causes the oversecreation of some cytokines associated with 
inflammation, endothelial dysfunction and thrombosis 26. Adipose tissue is also thought to 
cause under secretion of a beneficial adipokine called adiponectin 26. Adiponectin suppresses 
the attachment of monocytes to endothelial cells, thereby protecting against vascular damage 
26. People with diabetes have lower levels of adiponectin than those without diabetes and 
weight reduction increases with adiponectin levels 26.  
2.5 Screening 
Type 1 Diabetes Mellitus: Because of the acuteness of symptoms, screening for type 1 DM is 
not recommended 3. 
Type 2 Diabetes Mellitus: Testing should be considered at an earlier age and more frequently 
in individuals with risk factors 3. The recommended screening test is the fasting plasma 
glucose (FPG) or oral glucose tolerance test (OGTT) 3.Testing should be done every 2 years 
starting at 10 years of age or at the onset of puberty if it occurs at a younger age 3. 
2.6 Clinical presentation 
Type 1 DM: It can occur at any age thin individuals and are prone to develop diabetic 
ketoacidosis after several days of polyuria, polydipsia, polyphagia, and weight loss 3.  
Type 2 DM: Patients are often diagnosed secondary to unrelated blood testing, as they fail to 
present with symptoms 3. Lethargy, polyuria, nocturia, and polydipsia can be seen at 
diagnosis, but significant weightloss at diagnosis is less common 3. 
2.7 Diagnosis of diabetes 
Patients with either IFG or IGT are now commonly referred to as having 
“prediabetes” because of a higher risk of developing diabetes in the future 3.  Diagnosis is 
now based on any of the three criteria that follow: 
 Classic symptoms of diabetes (polyuria, increased thirst, unexplained weight loss, 
blurred vision) and a random plasma glucose concentration of _200 mg/dL (11.1 
mmol/L) 27. 
 Impaired glucose tolerance (IGT), is defined as a 2-hour postload plasma glucose 
value ≥140 mg/dL (7.8 mmol/L), but less than 200 mg/dL (11.0 mmol/L) during a 
standard 75g OGTT 3, 27.  
 Impaired fasting glucose (IFG) is plasma glucose of at least 100 mg/dL (5.6 mmol/L) 
but less than 126 mg/dL (7.0mmol/L) after an overnight (at least 8 h) fast (DM. 5) 3. 
 The fasting glucose reflects hepatic glucose production, which depends on insulin 
secretory capacity of the pancreas 3.  
 The postprandial glucose reflects uptake of glucose in peripheral tissues (muscle and 
fat) and depends on insulin sensitivity of these tissues 3.  
 HbA1c measurements are the gold standard for following long-term glycemic control 
and risk of microvascular complications in persons with diabetes for the previous 2 to 
3 months 3, 28. 
2.8 Treatment 
2.8.1 Desired outcome: The primary goals of DM management includes 3 
 To reduce risk for microvascular and macrovascular disease complications.  
 To ameliorate symptoms. 
 To reduce mortality and improve quality of life.  
 To prevent poor wound healing & decreased white blood cell function. 
 To prevent Diabetic ketoacidosis and hyperosmolar hyperglycemic state.  
 To maintain blood pressure as near normal as possible.  
2.8.2 Monitoring complications 
Current recommendations continue to advocate yearly or less frequent eye 
examination implemented on the advice of an eye care specialist 3. The feet should be 
examined and the blood pressure assessed at each visit 3. Yearly testing for microalbumin in 
urine and lipid abnormalities (or more) if needed to achieve lipid goals, is recommended 3. 
2.8.3 Self-monitoring of blood glucose 
Frequent SMBG enables patients to know their blood glucose concentration at 
any moment easily and relatively inexpensively to achieve near-normal blood glucose 
concentrations and to assess for hypoglycemia 3.  
2.8.4 Non pharmacologic therapy 
 Medical nutrition therapy is recommended for regulating drug administration 
with a balanced diet (<7% of total calories) to achieve and maintain a healthy body weight in 
diabetic patients 3.All diabetic patients should be encouraged to exercise, according to their 
age and physical capability 22. Exercise improves carbohydrate metabolism, insulin 
sensitivity and cardiovascular function, contributes to weight loss or maintenance, and 
improves well-being 22. It is also a useful component of any weight reduction program 
although diet may be more effective in promoting weight loss and metabolic control 22. 
 
2.8.5 Pharmacologic therapy 
                        Currently, six classes of oral agents are approved for the treatment of type 2 
diabetes:  sulphonyl ureas, Thiazolidinones, Aldose reductase inhibitors, α- glucosidase 
inhibitors, Biguanides, Dipeptidyl peptidase -4- inhibitors, Meglitinides, Micellaneous agents 
22.  Oral antidiabetic agents are often grouped according to their glucose- lowering mechanism 
of action 3.  
 Insulin sensitizers (that has ability to reduce insulin resistance): Biguanides & 
thiazolidinediones [TZDs] or glitazones 3. 
 Insulin secretagogues (that enhances endogenous insulin release): Sulfonylureas, 
Meglitinides3. 
2. PHARMACOECONOMICS 
“Pharmacoeconomics is the description and analysis of the costs of drug 
therapy to health care systems and society”30. It is a branch of health economics dealing with 
costs and benefits of drug therapy applied to the health care industry31, 32. It is taking on 
greater prominence in our health care system as costs continue to increase rapidly31. 
However, assessing the clinical data is the first part of economic evaluation and judgments 
about the role of new and existing drug therapies will often be based primarily on the clinical 
evidence of benefits and harm33. 
                        Cost outcome analyses are based on clinical studies of efficacy or 
effectiveness31. Before a cost outcome analysis is performed, the clinical issue (ex: Symptom 
management) must be identified and potential solutions measured for effectiveness31. 
Effectiveness refers to the benefit of an intervention when used in the “real world” where 
patient may have other co-existing conditions, take other medications, or may not be as  
compliant31. It is concerned with three areas of analysis: 30 
1. Comparison of drug therapy with other treatment modalities.  
2. Cost effectiveness of alternative drugs.  
3. Methods and procedures to improve cost effectiveness.  
 
3.1  Specific tools in Pharmacoeconomic analysis to allow the orderly and  
comprehensive collection of data.30 
1. Cost-Benefit Analysis 
2. Cost-Effectiveness Analysis 
3. Cost-of-Illness Analysis 
4. Cost Minimization Analysis 
5. Cost Utility Analysis 
6. Cost Consequences analysis 
3.1.1 Cost-Benefit Analysis:Cost benefit studies provide the most direct comparisons of costs 
with benefit; but they can also be most controversial31. All outcomes are valued in dollars, 
thus the study asks whether the dollar value of benefit is larger than the dollar value  of the 
costs31. Cost benefit studies may place dollar values on medical care costs saved, in addition 
to days off from work, days of reduced productivity at work because of illness31. It is 
appreciated that while the costs of specific treatment are easy to obtain (drug costs) that of the 
consequences (eventual therapy, support costs) are variable and difficult to estimate 30. 
3.1.2 Cost-Effectiveness Analysis: Cost effectiveness is broadly used term inside and outside 
the healthcare community 31.The costs of treatment to achieve specific therapeutic objectives 
are assessed30. In pharmacoeconomics, these studies measure dollars spent per outcome 
achieved, in which the outcomes (ie. Effectiveness) are measured in natural units 31. 
3.1.3 Cost-of-Illness Analysis: Cost of illness studies measure the lifetime cost for an 
incident case of a condition (i.e cost over a lifetime for individuals with a condition, even if 
the condition is not lifelong) 31. 
3.1.4 Cost Minimization Analysis: Cost minimization studies compare two or more treatment 
options that achieve the same or a defined minimum outcome 31, (costs of alternative 
equivalent treatments) 30.  
3.1.5 Cost Utility Analysis: Cost utility studies are a specific type cost effectiveness analysis 
in which two interventions are compared on preferences for different health states31. The 
health states are measured by morbidity & mortality31. Morbidity is defined based on quality 
of life measures and for cost utility studies, morbidity is combined with mortality to create a 
QALY31. The outcome of treatment is measured in terms ofquality of life, willingness to pay 
or patient preferencefor one treatment over another30. Although this appearsto be an index of 
consumer satisfaction, choices areinfluenced by several factors31. Attempts atdefining 
outcome in terms of quality of life per additional year of life (QALYs) may be suitable in 
measuringthe effect of treatment of a fatal disease 30.  
3.1.6 Cost consequence analysis: Cost consequence studies compares the cost of an 
intervention with the consequences or outcomes; however the consequences are not 
considered based on monetary value (ex: dollars per outcome), and there is no summary 
measure31. Each consequence is considered individually31. The collection of all costs of 
treatment (drugs, personnel, process) and their consequences (return to employment, cost of 
nontreatment or eventual therapy), both measures is expressed in financial terms30. 
3.2  Perspective 
                        Perspective is the key point that is to be considered for any economic 
evaluation34. Here it is mandatory from whose point of view the evaluation should be 
considered, from health care perspective involve (direct cost) or societal perspective 
(involves indirect cost) 34. How much a drug cost depends on your point of view?  
From:- 
1. Patient’s perspective: out-of-pocket expenses are cost 33.  
2. Societal perspective: It is the most comprehensive, as it includes all cost and benefit 
irrespective of who pays and who benefits, but often more limited perspectives are 
adopted 33. 
3.3  Costs 
                        Costs are clearly an important component of cost outcome analysis, thus it is 
critical to understand how costs are defined31. The costs of an intervention include the 
quantities of intervention used, the price of the intervention, the “labor” is administering the 
interventions, preparations and evaluation and other ongoing costs31. Clearly, cost 
calculations need to be transparent in a published cost outcome analysis because determining 
which costs to include can significantly affect the results31.  
1. Direct cost: - Direct cost are those associated directly with the delivery of medical 
care33. 
2. Indirect cost : - Indirect costs are those associated with lost production capacity (ex: 
time cost from work due to illness or death) 33. 
Most recently, an alternative costing terminology has been proposed cost may be classified 
as:- 
1. Health care sector costs: - resources used in providing initial and continuing care 33. 
2. Patient and Family sector costs: - Out-of-pocket expenses, cost associated with 
seeking care, time lost by patient and family33. 
3. Other sector cost : - home care and volunteer services33. 
3.4  Incremental costs 
                        This is the incremental cost of treatment with new therapy compared with the 
alternative what goes into calculation varies with the perspective of analysis, but the focus is 
on what is different between the two therapies rather than concentrating efforts on calculating 
the total costs of treatment with drug A and cost of treatment with alternative B in detail33. 
3.5  Discounting 
                         When cost and benefits extend over a number of years, discounting is used to 
reflect the fact that values from today‟s perspective depend on when costs are paid and 
benefit accrue33. Typical discount rates applied range from 3-6% 33. Other rates can be tested 
in sensitivity analysis33. NICE guidance recommends discounting rates of 6% of costs and 1-
5% for benefits with equal discounting benefits (6% costs, 0% benefits) tested in sensitivity 
analysis33. 
 
4.  ADVANTAGES OF PHARMACOECONOMIC ANALYSIS 
WHO defines health as being at only the absence of the disease and infirmity 
but also presence of physical, mental and social well being16. Health and economic 
development are positively linked and external investment is needed to break the vicious 
cycle of poor health and poverty that afflicts the less developed countries 36. Good health is a 
pre requisite to successful human endeavor and therefore core to economic growth and 
activity14. The demand for and the cost of the health care are increasing in all countries as the 
improvement in and sophistication of health technologies37.The increase in health care 
spending is mainly because of increased life expectance, increased technology, increased 
standard of living and increased demand in health care quality and services37.  
Medicines form a small but significant proportion of total health care cost37. 
Cost of medicines are marketed and are under patent law, preference of drug therapy over 
invasive therapy, discovering various labels uses of existing drugs and the irrational drug 
prescription37. Since 1961, pharmaceuticals are fallen under price regulation in India37. A 
total of 43 drugs accounting for 85% of the drug market were under price control in 197937. 
With successive polices, the number diminished and now a mere 15-20% of the drug market 
is under price control37. All over the world patients are affected by high price of medicines37.  
Health related quality of life (HRQoL) is increasingly used as an outcome 
indicator alongside conventional biomedical measures 23. QoL assessment focuses attention 
on patients‟s life beyond symptoms and signs 40. QoL also helps in policy research including 
programme evaluation and resource allocation 40. HRQoL is considered a patient assessed or 
patient centered outcome that relates to the individula‟s health perceptions, wellbeing and 
functioning rather than of diseases and disorders, hence is more comprehensive and 
compatible with WHO‟s (World Health Organization) concept 23, 40. Since complications are 
known to reduce HRQoL, intensified glycemic control is an important way to reduce the risk 
of complications and improve HRQoL. Rising health care costs have led to more focus on the 
need to prevent disease and to promote health as a longer term strategy for cost-containment 
42. These tools are potentially helpful to help to „do the right things right” but this objective is 
easier said than done 42.  
5.  NEED FOR PHARMACOECONOMIC ANALYSIS IN INDIA 
In a developing country like India 85% of total health expenditure is financed 
by house hold out-of-pocket expenditure on drug imposes a major financial burden on 
households37. A major portion of private health care spending goes to drug and per capita 
private drug spending in India is estimated as USD 1637. Hence many poor people frequently 
face a choice between buying medicines or buying food or other necessities due to limited 
resources and high pricing of drug. So medicine prices do matter37.  
Diabetes is traditionally known as a „Silent disease‟ exhibiting no symptoms 
until it progresses to severe target organ damage17. Because of its adverse effects and the 
associated economic burden on the health care system for individuals & society, diabetes is a 
major public health problem 38, 39. The prevalence of DM is rapidly rising all over the globe at 
an alarming rate 40. The expenses associated with caring for persons with diabetes are 
staggering7. Medical expenditure for people with DM is 2-3 times higher than those not 
affected by DM 39. Every year a large percentage of total health care budgets are spent on 
DM related costs24. Proper treatment of diabetes is not costly; not treating diabetes is very 
costly14. Although efforts to control hyperglycemia and associated symptoms are important, 
the major challenges in optimally managing the patient with diabetes are targeted at reducing 
or preventing complications and improving life expectancy and quality of life 3. Good 
glycemic control can delay the onset and slow progression of diabetic complication and 
thereby help in avoiding health expenditures 41. Intensive treatment, based on current 
guidelines, might lead to lower health care costs 24. 
The diabetes economics literature is extensive and diverse 39.Despite several 
advances in the approach to estimating the costs of DM, there is no standard for estimating 
these costs 39. It is well established that the care and treatment of DM patients consumes large 
amounts of health care resources, pharmacoeconomics on diabetes enables health care payers 
to budget appropriately, estimating the burden of illness and cost of treatment for DM 
becomes more important 43. Qualifying prevalence of DM and the number of people affected 
by DM, now and in future, is important to allow rational planning and allocation of resources 
44.  The significance of the epidemiological burden of DM lies in the complexity of these 
metabolic diseases which, if left untreated or not appropriately treated, may develop into 
complications, many of which are life- threatening, that inevitably resulting in different costs 
of treatment of complications 43. 
Pharmacoeconomics serves as a link between medicine and market 
economy32. The term pharmacoeconomics implies the application of economic principles to 
evaluation of pharmaceuticals33. Pharmacoeconomics offers reliable and meaningful 
information and serves as a tool for decision making in the choice of therapeutic approach32. 
The aim is to maximize health benefit for the community to be delivered considering the 
existing limited financial resources32. 
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II. LITERATURE REVIEW 
Guillermin et al., (2011) has conducted a cost minimization analysis 
comparing the long-term costs of insulin glargine once daily versus insulin detemir once or 
twice daily (for type 1 (T1DM) and type 2 (T2DM) diabetes mellitus using a validated 
computer simulation model, the CORE Diabetes Model from a Canadian provincial 
government‟s perspective. Costs were discounted at 5% per annum. Lifetime direct medical 
costs including costs of insulin treatment and diabetes complications were projected, 
assuming that all patients stay on the same treatment for life. T1DM and T2DM patients‟ 
daily insulin dose was derived from a meta-analysis of randomized trials. The meta-analysis 
showed T1DM and T2DM patients had similar HbA1c change from baseline when receiving 
IGlarg compared to IDet. Treatment of T1DM patients with IGlarg versus IDet BID resulted 
in lifetime cost savings of $4231 per patient. Treatment of T2DM patients with IGlarg 
resulted in lifetime cost savings of $4659 per patient versus IDet QD and cost savings of 
$8709 per patient versus IDet BID. Similar HbA1c change from baseline can be achieved 
with a lower IGlarg than IDet dose showing that with IGlarg instead of IDet can generate 
long-term cost savings45.  
Lee et al., (2011) estimated the cost-effectiveness of a once-daily GLP-1 
analog Victoza [Novo Nordisk] versus a thiazolidinedione, rosiglitazone in patients with 
T2DM including background therapy with glimepiride. The CORE Diabetes Model was used 
to compare 35-year clinical and economic outcomes associated with liraglutide 1.2 mg & 
glimepiride and liraglutide 1.8 mg & glimepiride versus rosiglitazone 4mgþ glimepiride. 
Baseline cohort characteristics were based on the Liraglutide Effect and Action in Diabetes-1 
trial and primary outcomes included life expectancy (LE), quality-adjusted life-years 
(QALYs), total costs and incremental cost-effectiveness ratios (ICERs). When compared to 
rosiglitazone, liraglutide 1.2 mg and 1.8 mg increased mean LE by 0.968 and 1.041 years, 
and QALYs by 0.764 and 0.837, respectively. Total lifetime costs increased by $26 094 for 
liraglutide 1.2 mg versus rosiglitazone, and by $47 041 for liraglutide 1.8 mg versus 
rosiglitazone. ICERs for liraglutide 1.2 mg versus rosiglitazone and 1.8 mg versus 
rosiglitazone were $34 147 and $56 190, respectively. Compared to rosiglitazone 4 mg plus 
glimepiride, liraglutide (at the 1.2-mg dose) plus glimepiride is a cost-effective treatment 
option for improving glucose control in T2DM46.  
Francis et al., (2011) has examined progression to type 2 diabetes and 
compared healthcare utilization and costs among patients with pre-diabetes, with or without 
comorbid hypertension, from a large national claims database (2003–2008). Patients were ≥ 
18 years of age with a medical claim or lab value indicating the presence of pre-diabetes. The 
index date was the first pre-diabetes diagnosis or qualifying lab value of fasting plasma 
glucose or impaired glucose intolerance. Multivariate analysis was conducted to identify risk 
factors affecting progression to type 2 diabetes, and to estimate the impact of hypertension 
status and diabetes progression on healthcare utilization and cost.  144,410 patients met study 
criteria, with an average follow-up of 802 days. Among participants, 30.7% progressed to 
diabetes, with a mean 288 days from pre-diabetes identification to diabetes diagnosis. 
Compared with patients who did not progress, the total adjusted medical costs for patients 
who developed diabetes increased by $1429 in 1 year, $2451 in 2 years, and $3621 in 3 years. 
Patients with concomitant hypertension were significantly more likely to progress to type 2 
diabetes, and had higher total medical costs compared to patients without hypertension. 
Patients with pre-diabetes who progressed to type 2 diabetes had higher healthcare utilization 
and costs compared with patients who did not. The presence of hypertension substantially 
increased costs and was associated with higher likelihood of diabetes progression47.  
Cleveringa et al., (2010) has performed a cluster randomized trial on cost-
effectiveness analysis of Diabetes Care Protocol versus usual care from a Dutch health care 
perspective with 1-year follow up and data were extrapolated using a modified micro 
simulation diabetes model, computing individual lifetime health-related costs, and health 
effects. Incremental cost-effectiveness ratios (ICERs) and cost-effectiveness (QALYs) were 
estimated using multivariate generalized estimating equations and acceptability curves were 
created. DCP patients lived longer, experiencedmore QALYs, and incurred higher total costs, 
per QALY gained. DCP had a more favorable effect on CVD+ patients than for CVD- 
patients. Coronary heart diseasecosts were reduced.DCP reduces cardiovascular risk, 
resulting in only a slight improvementin QALYs, lower CVD costs, but higher total costs, 
with a high cost-effectiveness ratio. Cost effectivecare can be achieved by focusing on 
cardiovascular risk factors in type 2 diabeticpatients with a history of CVD24.  
Palmeret al., (2010)has estimated the cost-effectiveness of BIAsp 30 versus 
IGlarg in the Chinese setting using validated and peer reviewed CORE Diabetes Model. The 
nephropathy, retinopathy, and stroke sub models were modified to incorporate available 
clinical data. Diabetes complication costs were derived from hospital surveys. Simulated 
cohorts and insulin treatment effects were based on the Once Mix study for once-daily BIAsp 
30 versus IGlarg and on the INITIATE study for twice-daily BIAsp 30 versus IGlarg. Life 
expectancy and direct medical costs were calculated and projections were made over 30-year 
time horizons, with a discount at 3% annually. Extensive sensitivity analyses were 
performed, including adjustments to cardiovascular risk. Once-daily BIAsp 30 increased life 
expectancy by 0.04 years and reduced direct medical costs (Chinese Yuan (CNY)) compared 
with IGlarg in the OnceMix-based analysis. Twice daily BIAsp 30 increased life expectancy 
by 0.08 years and reduced direct medical costs compared with IGlarg in the INITIATE-based 
analysis. Cost savings were attributable to lower lifetime insulin costs for BIAsp 30 
compared with IGlarg. Lowered risk of cardiovascular, reduced the projected clinical 
improvements for BIAsp 30 but increased treatment-related lifetime cost savings. BIAsp 30, 
either once- or twice-daily, improved projected life expectancy or reduced projected costs 
compared with IGlarg in the Chinese setting48.  
Tunceli et al., (2010) has performed a cohort study using the Health Core 
Integrated Research Database identified T1DM and T2DM patients age ≥18 and ≤ 65 years 
between 1/1/2006 – 12/31/2006 to compared the annual direct healthcare cost among T1DM 
and T2DM patients using two cost estimation methods: (1) DM-attributable cost and (2) all 
cause case–control cost. DM-attributable cost was assessed by summing medical claims for 
DM and pharmacy claims for antihyperglycemic agents, and all cause health care cost was 
assessed for cases and controls. A total of 12,096 T1DM and 256,245 T2DM cases and 
matched controls were identified. T1DM and T2DM cases had significantly higher average 
baseline comorbidities and Deyo–Charleson Comorbidity scores than controls. While DM 
attributable cost estimation resulted in a mean annual cost of $6247 for T1DM and $3002 for 
T2DM in 2007, the mean annual (per patient) all-cause total cost estimation using the case–
control method resulted in a difference of $10,837  for T1DM; and $4217 for T2DM. DM-
attributable cost method underestimated costs by 42% for T1DM and 29% for T2DM 
compared to the case–control method. The difference was smaller but still significant when 
multivariate technique was used. Patients with DM may use a substantial amount of medical 
& pharmacy services and attributable cost method may underestimate the total cost49.  
Menzin et al., (2010) has conducted a retrospective cohort analysis to asses 
the potential relationships between glycemic levels, diabetes-related hospitalizations, and 
costs among adult patients with either type 1 or type 2 diabetes mellitus who were assigned to 
a primary care provider (PCP) in a clinic. Data from approximately 200,000 members of the 
Fallon Clinic Health Plan who were assigned to a clinic PCP at any time during a 5-year 
study period beginning starting with each patient‟s first A1c test and continued until plan 
disenrollment. In the logistic regression analysis, odds of having at least 1 diabetes-related 
hospital stay did not significantly differ for patients with mean A1c of < 7% compared with 
patients in most higher mean A1c categories; however, odds of having a diabetes-related 
hospitalization were significantly higher for patients with mean A1c of 10% or more 
compared with patients with mean A1c of < 7%. In the negative binomial regression analysis 
of those with at least 1 hospital admission, estimated costs per hospitalized patient increased 
by mean HbA1c level. In the Poisson regression analysis, the rate of diabetes-related 
hospitalizations significantly increased by A1c level. In the 2-part model results, adjusted 
mean estimated costs of diabetes-related hospitalizations per study patient were $2,792 
among those with mean A1c of < 7% and $6,759 among those with mean A1c of 10% or 
more. In this managed-care plan, the odds of having at least 1diabetes-related hospitalization 
were not significantly associated with higher mean A1c except for patients with mean A1c of 
at least 10%, however, higher mean A1c levels were associated with significantly higher 
estimated hospitalization costs among those with at least 1 hospitalization and with higher 
rates of diabetes-related hospital utilization per 100 patient-years50. 
Al-Maskari et al., (2010) has estimated the direct annual treatment costs of 
DM and its related complications among patients in Al-Ain city, UAE. A sample of 150 DM 
patients were enrolled during 2004-2005, and their medical costs over the ensuing 12 months 
was measured, quantified, analyzed and extrapolated using conventional and inference 
statistics. The total annual direct treatment costs of DM among patients without 
complications, was US $1,605 which is 3.2 times higher than the per capita expenditure for 
health care in the UAE during 2004. However, this cost increased 2.2 times with the presence 
of DM related complications for patients with microvascular, 6.4 times for patients with 
macrovascular and 9.4 times for patients with both micro and macrovascular complications. 
Likewise, the annual direct hospitalization costs of DM patients increased by 3.7 times for 
patients with microvascular complications, by 6.6 times for patients with macrovascular 
complications and by 5 times for patients with both micro and macrovascualr complications. 
Hospitalisation costs constituted a large proportion and were increasingly higher with the 
presence and progression of DM related complications. To reduce the impact on healthcare 
resources, efforts should be made to prevent progression to DM complications, by 
implementing guidelines for diabetes care, screening for complications and better 
management51.  
Kapooret al., (2010) performed a cross-sectional study was conducted among 
adult Saharia, a primitive tribal group of Madhya Pradesh. A total of 364 subjects ranging in 
age group 18 - 60 years were divided into two groups based on their random blood sugar 
level. Stature, weight, waist circumference, hip circumference, skin fold thicknesses, fat 
percent, blood pressure and blood sugar level were measured for all the subjects. 8.9% males 
and 7.1% females were found to be having more than 140 mg/dl random sugar level. All the 
skin fold thicknesses, body circumference, indices of adiposity, fat percentage and blood 
pressure were found to be significantly higher among the „pre-diabetic males‟. The picture 
was not so clear among females. Saharia is a socio-economically weaker population with 
very low literacy level but the clustering of higher blood sugar level, higher blood pressure 
and higher fat percentage is an indicator of a beginning of metabolic syndrome among this 
primitive tribal group showing a paradoxical situation52.  
Lage et al., (2009) has compared costs of Exenatide and sitagliptin among 
patients with type 2 diabetes treated with either of these agents. Data with dates of service 
from September 1, 2005 through August 31, 2007, were obtained from a large US 
retrospective claims database. Intent-to-treat cohorts of adults diagnosed with T2D who 
began taking either exenatide (n=1885) or sitagliptin (n=2482) and did not use the alternate 
medication in the 6-month follow-up period were created. Six-month total medical costs were 
estimated and examined using either stepwise multivariate regressions or a two-part model 
that controlled for the probability of using the medical service. The analysis controlled for the 
potential impact of patient demographics, general health, prior resource use, co-morbidities, 
and timing of treatment initiation. Exenatide was associated with lower total 6-month direct 
medical costs and outpatient costs, despite some component costs being slightly higher with 
exenatide: diabetes-related drug costs, diabetes-related medical costs, and emergency room 
costs. Compared with the use of sitagliptin, exenatide was associated with lower total medical 
costs (difference of $655) despite higher total diabetes-related costs (difference of $140). As 
a result, there appears to be overall cost savings associated with the use of exenatide relative 
to sitagliptin53.  
Afkhami-Ardekani et al., (2009) has conducted a cross sectional study to 
assess the prevalence of type 2 diabetes complications and their contributing factors, carried 
out on 1000 the type 2 diabetic patients referred to Yazd Diabetes Research Center. All 
diabetic patients underwent the specific tests for retinopathy, nephropathy, neuropathy, 
peripheral vascular diseases and cardiovascular diseases. Logistic regression analysis was 
used to find out strength of association of risk factors with a specific complication. In this 
study 1000 type 2 diabetic patients were studied. Nephropathy was diagnosed in 285, 
retinopathy in 519, CAD in 251, PVD in 143, CVA in 109 and foot ulcer in 84 patients.In this 
study the most important contributing factors in diabetic complications were age, duration of 
diabetes, blood pressure, glycated hemoglobin and Body Mass Index. So glycemic and blood 
pressure control can prevent diabetic complications or at least delay them54.  
Ramesh et al., (2009) has conducted a prospective, open label, randomized 
study in a South Indian state for nine months to assess the impact of pharmacist provided 
patient education on knowledge, attitude, practice (KAP) and quality of life in Type 2 
diabetes mellitus patients. 78 patients meeting the study criteria were randomized into control 
and test group through envelope method. 70 patients completed all the follow-ups of the 
study. Content and translation validated KAP questionnaire and Ferrans and Powers quality 
of life questionnaire were administered to assess the influence of education. The validated F 
& P questionnaire was supported by an internal consistency á = 0.96 and a temporal stability 
r = 0.89 and construct validity r = 0.88. The test group patients received pharmacist provided 
patient education regarding drug therapy, diet, exercise and life style modifications through 
the verbal and written education material (PIL) in regional language. The control group 
patients received patient education at the end of the study. A significant improvement was 
observed with respect to knowledge, practice and attitude towards disease management, QOL 
scores in various domains and a significant decrease in blood glucose (P < 0.05) was 
observed in test group patients41.  
Palmer et al., (2008) has studied the long-term clinical and cost-effectiveness 
of switching to Biphasic Insulin Aspart in poorly- controlled Type 2 Diabetes Patient in 
Chinese setting using a computer simulation CORE Diabetes Model. Previous data on 
treatment effects and patient characteristics were obtained from Physicians‟ Routine 
Evaluation of Safety and Efficacy of NovoMix 30 Therapy, a multi country, single-arm, 
observational study where type 2 diabetes patients poorly controlled with biphasic human 
insulin were converted to biphasic insulin aspart 30; the Chinese subgroup experienced an 
improvement in HbA1c and a reduction in hypoglycemic events. Extensive sensitivity 
analyses were performed. Conversion to BIAsp30 was associated with increased direct 
medical costs of Chinese Yuan (CNY) 1751 per patient, due to higher pharmacy and 
management costs (CNY+19,007), offset by reduced diabetes-related complication costs 
(CNY –17,254) over patient lifetimes. BIAsp30 was associated with an incremental cost-
effectiveness ratio of CNY 1926 per QALY gained and clinical outcomes was improved but 
associated with increased lifetime medical costs. BIAsp30 would be considered cost-effective 
in China given a willingness-to-pay threshold of CNY 100,000 per QALY gained in type 2 
diabetes patients poorly controlled on BHI55.  
Tunis et al., (2008) has evaluated the long-term cost-effectiveness of 
pioglitazone compared to rosiglitazone in treating patients with T2DM and dyslipidemia, and 
determine the extent to which reported beneficial lipid effects of pioglitazone would improve 
clinical and economic outcomes through reduced macrovascular complications. The validated 
CORE Diabetes Model was used to simulate changes in glycosylated hemoglobin, 
complications, and direct medical costs, double-blind trial comparing lipid and glycemic 
effects of pioglitazone and rosiglitazone among individuals with T2DM and untreated 
dyslipidemia. Sensitivity analyses examined the impact of cohort, clinical, and cost inputs on 
incremental cost effectiveness ratios (ICERs). In the base case, pioglitazone was associated 
with mean quality-adjusted lif years (QALYs) of 7.476 (0.123) vs. 7.326 (0.128) for 
rosiglitazone. Pioglitazone had $3038 higher total direct costs, but $580 lower complication 
costs. Risks of four cardiovascular complications were reduced with pioglitazone, while risks 
of 17 other complications were slightly higher. The ICER for pioglitazone treatment was $20 
171/QALY. Results were most sensitive to the effects of HbA1c, high-density lipoprotein-
cholesterol, overall lipid effects, and pioglitazone acquisition costs56.  
Schofield et al., (2008) has examined the association between long-term 
health conditions and being out of the labour force among older Australians. Retrospective 
analysis of cross-sectional data from the Australian Bureau of Statistics 2003 Survey of 
Disability, Ageing and Carers for people aged 45–64 years. Main outcome measuresof gross 
domestic product lost as a result of  premature retirement associated with ill health. 9198 
people surveyed were aged 45–64 years, 3010 of whom were not in the labour force. Of 
these, 1373 had retired because of a chronic health condition, most commonly a back 
problem, or arthritis and related disorders. When adjusted for age and sex, all conditions 
studied except diseases of the ear and mastoid process, other endocrine/nutritional and 
metabolic disorders, noise- induced deafness or hearing loss, and high cholesterol were 
significantly associated with being out of the labour force. Extrapolating from these results, 
an estimated 663 235 older Australians were not working because of ill health, reducing 
Australia‟s gross domestic product by around $14.7 billion per annum. Prevention of long-
term health conditions may help older Australians remain in the labour force longer, thereby 
increasing revenue to fund health care for the ageing population57.  
Crivera et al., (2006) has estimated the incremental medication cost of 
providing optimal therapy to reach recommended goals versus actual therapy in patients with 
T2DM. A total of 601 type 2 diabetes patients receiving care from the outpatient clinics from 
March 1, 1996–August 31, 1997, selected randomly and abstracted clinical- medication data. 
Treatment algorithms based on 2004 clinical practice guidelines were applied for 
hyperglycemia, hyperlipidemia, and hypertension to patients‟ current medication therapy to 
determine how medication regimens could be improved to attain recommended treatment 
goals to assess the Mean incremental medication costs, the cost differences between current 
and recommended therapies. Average annual medication cost/patient would increase from 
$1525 to $2164 and annual incremental costs/patient increased by $168 for 
antihyperglycemic medications, $75 for antihypertensive medications, $392 for 
antihyperlipidemic medications, and $3 for aspirin prophylaxis. Average yearly incremental 
cost of recommended laboratory testing ranged from $77–$189/patient, optimizing drug 
regimens to achieve recommended treatment goals for type 2 diabetes was approximately 
$600/patient. These results provide valuable input for assessing the cost-effectiveness of 
improving comprehensive diabetes care58. 
Esposti et al., (2004) performed a clinical practice-based analysis of how long 
patients remain on various antihypertensive drugs. An administrative database listing of 
patient baseline characteristics, drug prescriptions, and hospita l admissions was used. All new 
users of antihypertensive drugs, ≥20 years of age, receiving a first prescription for diuretics, β 
blockers, CCBs, ACE inhibitors, or ARB antagonists for an entire year of 2000, were 
included and observed. A total of 14,062 patients were included in the study, 39.7% of whom 
remained on treatment provided. Persistent patients (duration of therapy > 273 days) were 
more likely to be older, taking other drugs for concurrent disorders, hospitalized for 
cardiovascular diseases, and initially prescribed ARB antagonists, accounted for 80.6% of the 
overall cost for antihypertensive drugs. Factors associated with drug cost were age, pattern of 
persistence, number of prescribed classes, and specific medication at enro llment, is needed to 
evaluate the appropriateness and the cost-effectiveness of drug use59.  
Palmer et al., (2004) has observed the application of the CORE Diabetes 
Model in type 2 diabetes using a simulated the long-term cost-effectiveness of repaglinide/ 
metformin combination therapy versus nateglinide/metformin for treatment of individuals 
with type 2 diabetes with an inadequate response to sulphonylurea, metformin, or fixed dose 
glyburide/metformin. HbA1c changes for each regimen were taken from a comparative study. 
At the end of the study, changes in HbA1c from baseline were –1.28% points and –0.67% 
points for repaglinide/ metformin and nateglinide/metformin, respectively. Costs were 
calculated as the annual costs for drugs plus costs of complications over a 30-year period. 
Outcomes and costs were discounted at 3% annually.With repaglinide/metformin, improved 
glycaemic control led to projected decreases in complication rates, improvement of LE and 
QALE by 0.15 and 0.14 years respectively and total cost savings of $3,662/person over the 
30-year period. Repaglinide/metformin had a 96% probability that the incremental costs per 
quality-adjusted life year gained would be $20,000 or less, and a 66% probability that 
repaglinide/metformin would be cost-saving compared to nateglinide/metformin. Sensitivity 
analyses supported the validity and reliability of the results. In the health economic context, 
repaglinide/metformin combination was dominant to nateglinide/metformin60.  
Bottomley., (2001) has performed a cross sectional postal T2ARDIS*survey 
and data were acquired from a random sample of people diagnosed with type 2 diabetes from 
population-wide diabetes registers. Aggregated resource use, implications for healthcare 
management, costs in the NHS and Social Services were considered. The data were compared 
to resource data in the general population to determine the impact of developing diabetic 
complications, particularly vascular disease. Implications for services were also considered. 
At a population level, on average one in four patients reported microvascular complications, 
one in 10 macrovascular complications and one in 14 reported both. Compared to the general 
population, people with T2DM were admitted to hospital more often and stayed longer as in-
patients. This trend was similar for out-patient care. Across the whole cohort, more than 40% 
of the NHS cost was due to in-patient care. Diabetic complications increased costs in the 
NHS and Social Services, costs of insulin products and other drugs. The average annual 
spend on oral antidiabetic drugs accounted for only 2% of NHS costs for diabetes. Most of 
the costs of care for the person with type 2 diabetes are borne by the NHS and the hospital 
sector61.  
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III. AIM AND OBJECTIVES 
Diabetes mellitus is a chronic potentially disabling disease commonly encountered by 
health care professionals that represents an important public health and clinical concern12, 62. 
Diabetes mellitus is a costly disease, both for the patient and the health care provider due to 
its chronicity and multi-organ involvement which resulted in frequent visit and admission to 
health facilities11.  
Pharmacoeconomics is a part of the tool bag; Pharmacist can be used to improve the 
efficacy of his profession. It adopts and applies the principles & methodology of health 
economics to the field of pharmaceutical policy 34. The cost benefit analysis facilitates 
decision making regarding the implementing, withdrawing or continuing of a program. Net 
social gains or loss make it easy for making decisions. Furthermore, CEA studies facilitate 
comparisons between different programs with different outcomes, since all outcomes are 
converted into monetary values63. 
The large cost is associated with diabetes and its treatment is unsustainable of most 
health care systems and hence there is increasing use of economic evaluation as a tool to 
allocate resources. These evaluates can track the current costs and assess the future expenses 
and resources allocation, which leads to the improvement of the quality of healthcare 63. 
Decisions about what treatment should be available within a healthcare system have always 
been influenced by the resources available to pay for them 34. Economics are an issue in 
diabetes care because patients require continues medication care, monitoring supplies and 
equipment, regular office appointments and patient self management education to prevent 
acute complications and to reduce the risk of long term complications23. 
Aim 
The aim of this study was to perform pharmacoeconomic evaluation of long term and 
clinical outcomes of patients receiving anti diabetic treatment and to compare the total direct 
medical costs with each drug treatment. This was a prospective study that included only the 
records of patient who received anti diabetic drugs to improve the quality of care and to 
improve the compliance of diabetes to the medical care provided.  
Objectives 
 To find the patient demographics of diabetic population 
 To assess their adherence to therapy and Quality of health care 
 To analyze their clinical data with ongoing therapy 
 To study  the prescribing pattern of the antidiabetic drugs  
 To analyze their cost of therapy & beneficence 
 To compare the cost and benefits among each drug used for treatment 
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IV.  PLAN OF WORK 
The present study was carried out for an entire period of 6 months from August 2011 to 
January 2011 to achieve the objective. The study was designed as outlined below. 
Stage I:  Preparatory study to identify the scope of the work.  
Stage II:  Literature survey. 
Stage III:  Compose study protocol. 
Stage IV:  Attain permission from the hospital authority.  
Stage V:  Contrive a data entry form 
Stage VI:  Data collection. 
Stage VII:  Analysis of procured data. 
Stage VIII:  Perform cost minimization analysis. 
Stage IX:  Execute cost effectiveness analysis based on cost minimization 
analysis. 
Stage X:  Submission of report. 
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V.  METHODOLOGY 
Study site 
The study was conducted at Monika Diabetic Care Centre, Erode. 
Consent from hospital authorities 
The proposal of the study including the aim, objectives, and plan of work was 
submitted to the director of the hospital and consent was obtained. 
Study duration 
The study duration was between August to December 2011. 
Analysis 
The duration of therapy (days elapsing between the 1st and the last 
prescription) and the mean daily dose were calculated45.  
Literature survey 
The extensive survey of literatures was carried out about the 
pharmacoeconomics of the anti-diabetic drugs, extensively prescribed. The literature was 
procured from primary, secondary and tertiary sources of drug information.  
Study design 
The study was performed as a retrospective method to analyze the 
pharmacoeconomics of drugs prescribed widely for their cost minimization and cost 
effectiveness, in management of diabetes mellitus.  
Sources of data 
All the indispensible and pertinent information are procured from the patient 
medication profile and direct interview with patients.  
Data entry form 
A distinctly contrived data entry form was used to enter patient‟s details like 
age, sex, food habits, occupational status, co morbid diseases, clinical data, diabetic 
complications and drugs used for treatment. The data collected for the study were analyzed 
and the report was submitted. 
Data procurement 
All the needful and applicable information are collected in a distinctive data 
entry form, while patients were waiting to see the Diabetician. Ethical approval for the study 
was obtained from the institutional ethics committee. Anonymity and confidentiality of the 
information provided by the patient was maintained throughout and after the present study.  
Study variables 
This was operationalised by assessing the usefulness of antidiabetics in 
diabetes management (International classification of diseases nineth revision (ICD-9) Code 
250xx); using QALY achieved from each type of drug administrated was obtained by “The 
Quality of Life Health Questionnaire” by Hadorn and Uebersax68. Incremental cost 
effectiveness ratio (ICER) is calculated based on the discounted incremental cost to 
discounted quality adjusted life in years.  
Cost analysis 
Direct costs of anti diabetic drugs were taken into account and evaluated at 
MIMS- Asia purchase price. Costs were expressed as overall and average values. The 
currency reference was the Indian rupees (`). The mean price of the drugs belonging to the 
„5‟pharmacological classes and their combinations available in market, weighed for the 
number of drugs administered for each individual drug was ` for Insulins, ` for Biguanides 
etc 45. 
Discounting  
Discounting of future costs and clinical outcomes (in terms of life in years) 
was performed with a discount rate of 3% per annum applied in the base case analysis based 
on WHO guidelines for cost effectiveness analysis48. 
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VI. OBSERVATIONS 
Table- 1: Data on patients enrolled for study.  
Number of Male patients 229 54.39% 
Number of Female patients 192 45.61% 
Total number of patients enrolled  421 100% 
 
 
Characteristics of patients with Diabetes: Age wise distribution 
Table- 2: Age wise distribution of Diabetes with Average duration and Body  
Mass Index (n= 407) 
Age Group 
(in years) 
Total  
(%) 
Duration 
(yrs range) 
BMI 
(Kg/m2) 
Male  
(%) 
Female  
(%) 
Below 20 0.74 1-5 11.27 0.25 0.49 
21-30 1.72 1-5 23.88 1.23 0.74 
31-40 9.58 1-5 24.62 6.88 2.70 
41-50 27.52 6-10 25.82 15.23 12.29 
51-60 33.66 6-10 26.19 17.44 16.22 
61-70 21.13 6-10 25.5 11.30 10.07 
71-80 5.16 11-15 25.34 2.70 2.46 
Above 80 0.25 1-5 21.46 0.25 0 
 
 
 
 
Table- 3: Occupational status and Weight variations of patients with Age wise  
Distribution (n= 407) 
Age Group Sedentary  Active  Pensioner  Wt gain Wt loss 
(in years) (%) (%) (%) (%) (%) 
Below 20 0.25 0.49 0 0 0 
21-30 0.49 0.98 0 0 0.49 
31-40 3.93 4.42 0 1.23 4.67 
41-50 13.27 11.06 0.98 2.21 11.30 
51-60 19.90 8.85 1.22 3.19 15.48 
61-70 14.99 2.95 2.21 2.21 9.34 
71-80 3.69 0.25 0.98 0.25 2.70 
Above 80 0.25 0 0 0 0 
 
Characteristics of patients with Diabetes: Duration wise distribution 
Table- 4. Duration wise distribution of Diabetes with Average Age and Body  
Mass Index (n= 407) 
Duration Group 
(in years) 
Total 
(%) 
Age 
(yrs 
range) 
BMI 
(Kg/m2) 
Male  Female  
No: (%) No: (%) 
New 0-1 13.26 41-50 24.52 38 9.34 16 3.93 
1-5 39.80 51-60 26.00 93 22.60 68 16.71 
6-10 24.32 51-60 24.83 44 10.81 56 13.71 
11-15 13.26 51-60 25.80 27 6.34 26 6.34 
16-20 6.88 51-60 25.97 15 3.69 13 3.19 
21-25 1.97 51-60 31.24 5 0.998 4 0.98 
Above 25 0.49 71-80 26.95 1 0.25 1 0.25 
 
 
Table- 5: Occupational status and Weight variations of patients with Age wise  
Distribution (n= 407) 
Duration Group 
(in years) 
Sedentary 
(%) 
Active  
 (%) 
Pensioner 
(%) 
Wt gain 
(%) 
Wt loss 
(%) 
New 0-1 6.88 5.90 0.25 0.98 7.86 
1-5 20.64 14.50 1.47 4.67 14.00 
6-10 15.72 6.39 1.47 1.72 11.55 
11-15 9.09 2.46 1.47 0.49 7.37 
16-20 4.67 0.74 0.74 0.25 2.70 
21-25 1.47 0.25 0.25 0.25 0.74 
Above 25 0.25 0.25 0 0.25 0.25 
 
Co-existing illness of patients with Diabetes: Age wise distribution 
Table- 6: Micro vascular complications (n= 407) 
Age Group 
(in years) 
Retinopathy  
(%) 
Foot ulcer 
(%) 
Nephropathy 
(%) 
Neuropathy 
(%) 
Below 20 0 0 0.49 0 
21-30 0.49 0 0.49 0.49 
31-40 2.70 0.98 3.44 3.44 
41-50 12.53 4.91 10.07 11.55 
51-60 15.97 7.62 14.50 18.67 
61-70 13.76 6.14 10.32 12.29 
71-80 4.18 1.97 2.21 2.70 
Above 80 0 0.25 0 0 
 
 
 
Table- 7: Macro vascular complications (n= 407) 
Age Group 
(in years) 
Hypertension 
(%) 
Dyslipidemia 
(%) 
Cardio 
Vascular 
Diseases 
(%) 
Peripheral 
Vascular 
Diseases 
(%) 
Below 20 0 0 0 0 
21-30 0 0 0 0 
31-40 2.21 1.97 0 0.49 
41-50 11.30 5.65 0.49 0.49 
51-60 15.48 7.37 3.19 0.98 
61-70 16.22 7.37 1.72 0.49 
71-80 3.44 0.98 0.49 0.25 
Above 80 0 0 0 0 
 
Co-existing illness of patients with Diabetes: Duration wise distribution 
Table- 8:  Micro vascular complications (n= 407) 
Duration Group 
(in years) 
Retinopathy 
(%) 
Foot ulcer 
(%) 
Nephropathy 
(%) 
Neuropathy 
(%) 
New 0-1 4.18 1.72 5.65 4.67 
1-5 18.43 7.86 17.20 19.90 
6-10 13.02 5.65 11.30 12.53 
11-15 8.11 3.69 4.91 7.37 
16-20 4.91 3.19 2.95 3.19 
21-25 1.72 0.74 0.74 1.72 
Above 25 0 0.25 0 0.49 
 
 
Table- 9: Macro vascular complications (n= 407) 
Duration 
Group 
(in years) 
Hypertension 
(%) 
Dyslipidemia 
(%) 
Cardio 
Vascular 
Diseases 
(%) 
Peripheral 
Vascular 
Diseases 
(%) 
New 0-1 4.18 1.97 0.25 0.49 
1-5 18.92 9.34 2.95 0.74 
6-10 11.79 5.90 0.49 0.98 
11-15 7.86 3.19 0.74 0.25 
16-20 3.44 2.21 1.23 0.49 
21-25 1.47 0.98 0.25 0 
Above 25 0.49 0 0 0 
 
Quality of Life of patients with Diabetes: Age wise distribution  
(Hadorn & Uebersax Scale68, Appendix II) 
Table- 10:  Suffering of patients (n= 407) 
Age Group 
(in years) 
None  
(%) 
Mild  
(%) 
Moderate  
(%) 
Severe  
(%) 
Below 20 0.49 0 0.25 0 
21-30 0.98 0.25 0 0 
31-40 5.90 1.47 0.25 0 
41-50 16.46 6.14 1.47 0 
51-60 23.59 5.90 0.98 0 
61-70 14.00 4.42 1.23 0 
71-80 2.70 1.47 0.49 0.25 
Above 80 0.25 0 0 0 
 
 
Table- 11: Physical Activity restriction of patients (n= 407) 
Age Group 
(in years) 
None  
(%) 
Mild  
(%) 
Moderate  
(%) 
Severe  
(%) 
Below 20 0 0.74 0 0 
21-30 0.49 0.74 0 0 
31-40 3.44 3.19 0.49 0.49 
41-50 9.34 9.82 2.21 2.95 
51-60 10.32 13.76 4.18 2.46 
61-70 7.37 8.11 2.95 1.23 
71-80 1.97 2.21 0.49 0.25 
Above 80 0.25 0 0 0 
 Quality of Life of patients with Diabetes: Duration wise distribution 
(Hadorn & Uebersax Scale68, Appendix II) 
Table- 12: Suffering of patients (n= 407)  
Duration Group 
(in years) 
None 
(%) 
Mild 
(%) 
Moderate 
(%) 
Severe 
(%) 
New 0-1 9.09 2.21 0.49 0 
1-5 24.82 8.85 1.97 0 
6-10 16.71 3.93 1.72 0 
11-15 8.85 2.70 0.49 0.25 
16-20 4.67 1.23 0.25 0 
21-25 1.23 0.74 0 0 
Above 25 0.25 0.25 0 0 
 
 
 
Table- 13: Physical Activity restriction of patients (n= 407) 
Duration Group 
(in years) 
None 
(%) 
Mild 
(%) 
Moderate 
(%) 
Severe 
(%) 
New 0-1 5.90 5.16 0.74 0.25 
1-5 12.04 14.74 6.14 2.70 
6-10 8.60 10.07 1.72 1.97 
11-15 4.42 5.16 1.23 1.23 
16-20 1.72 2.46 0.74 1.23 
21-25 0.49 0.98 0.25 1.23 
Above 25 0.49 0 0 0 
 
 
 
Table- 14: Therapy provided to selected patients (n= 388) 
Therapy Percentage of patients 
received treatment (%) 
Single Drug therapy 8.76 
2-Drug Combination therapy 38.92 
3-Drug Combination therapy 30.15 
4-Drug Combination therapy 15.21 
>4- Drug Combination Therapy 6.96 
 
 
 
 
 
 
 
Figure- 1: Therapy provided to selected patients (n= 388) 
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 Table- 15: Drugs provided to patients receiving Single Drug therapy (n= 388) 
Therapy Percentage of patients 
received treatment (%) 
Total 8.76 
BGS 5.67 
TGZ 0.26 
SUS 2.32 
INS 0.52 
BGS = Biguanides, TGZ = Thioglitazones, SUS = Sulphonyl Ureas, INS = Insulins 
 
 
Table- 16: Drugs provided to patients receiving 2-Drug Combination therapy (n= 388) 
Therapy Percentage of patients 
received treatment (%) 
Total 38.92 
1 AGI + 1 BGS 0.26 
1 AGI + 1 SUS 1.03 
1 BGS + 1 DPP IV 0.26 
1 BGS + 1 SUS 27.84 
1BGS + 2 SUS 2.32 
1 BGS + 1 TGZ 0.52 
1 AGI + 2 INS 1.03 
1 AGI + 1 INS 0.77 
1 BGS + 1 INS 0.26 
1 SUS + 1 INS 2.32 
1 INS + 2 SUS 0.26 
3 INS + 1 SUS 0.52 
1 SUS + 1 TGZ 1.55 
BGS = Biguanides, TGZ = Thioglitazones, SUS = Sulphonyl Ureas, INS = Insulins  
AGI = Alpha glucosidase inhibitors, DPP IV = DPP IV inhibitors 
  
Table- 17: Drugs provided to patients receiving 3-Drug Combination therapy (n= 388) 
Therapy Percentage of patients 
received treatment (%) 
Total 30.15 
1 AGI + 1 BGS + 1 DPP IV 0.26 
1 AGI+ 1 BGS+ 1 SUS 6.70 
1 AGI + 1 BGS + 2 SUS 2.32 
1 AGI + 1 BGS + 3 SUS 0.26 
1 BGS + 1 SUS + 2 DPP IV 0.77 
1 BGS + 1 SUS + 1 DPP IV 4.12 
1 BGS + 1 SUS + 1 TGZ 1.29 
1 BGS + 2 SUS + 1 TGZ 1.55 
1 INS + 1 BGS + 1 AGI 0.26 
2 INS + 1 BGS + 1 AGI 0.26 
1 INS + 1 AGI + 1 SUS 0.77 
2 INS + 1 AGI + 2 SUS 0.26 
2 INS + 1 AGI + 1 SUS 0.52 
3 INS + 1 AGI + 1 SUS 0.26 
1 INS + 1 AGI + 2 SUS 0.26 
3 INS + 1 BGS + 1 DPP IV 0.26 
1 INS + 1 BGS + 1 SUS 7.99 
4 INS + 1 BGS + 2 SUS 0.26 
2 INS + 1 BGS + 2 SUS 0.26 
2 INS + 1 BGS + 1 SUS 0.52 
1 INS + 1 BGS + 2 SUS 0.77 
1 INS + 1 DPP IV+ 1 SUS 0.26 
BGS = Biguanides, TGZ = Thioglitazones, SUS = Sulphonyl Ureas, INS = Insulins  
AGI = Alpha glucosidase inhibitors, DPP IV = DPP IV inhibitors 
 
 Table- 18: Drugs provided to patients receiving 4-Drug Combination therapy (n= 388) 
Therapy Percentage of patients 
received treatment (%) 
Total 15.21 
1 AGI + 1 BGS + 1 DPP IV + 1 SUS 2.84 
1 AGI + 1 BGS + 2 DPP IV + 1 SUS 1.03 
1 AGI + 1 BGS + 1 SUS + 1 TGZ 0.77 
1 INS + 1 AGI + 1 BGS + 1 SUS 2.58 
2 INS + 1 AGI + 1 BGS + 1 SUS 0.77 
3 INS + 1 AGI + 1 BGS + 1 SUS 1.29 
1 INS + 1 AGI + 1 BGS + 2 SUS 1.03 
2 INS + 1 AGI + 1 BGS + 2 SUS 0.52 
1 INS + 1 AGI + 1 BGS + 3 SUS 0.52 
1 INS +1 SUS + 1 AGI +1 DPP IV 0.52 
1 INS + 1 AGI + 1 SUS + 1TGZ 0.26 
1 INS + 1 BGS + 1 DPP IV + 1 SUS 0.52 
1 INS + 1 BGS + 1 DPP IV + 2 SUS 1.55 
1 INS + 1 BGS + 2 DPP IV + 1 SUS 0.26 
2 INS + 1 BGS + 1 DPP IV + 1 SUS 0.26 
1 BGS + 2 SUS+ 1 TGZ + 1 INS 0.26 
1 BGS + 3 SUS+ 1 TGZ + 1 INS 0.26 
BGS = Biguanides, TGZ = Thioglitazones, SUS = Sulphonyl Ureas, INS = Insulins  
AGI = Alpha glucosidase inhibitors, DPP IV = DPP IV inhibitors 
 
 
 
 
 
 
Table- 19: Drugs provided to patients receiving >4-Drug Combination therapy (n= 388) 
Therapy Percentage of patients 
received treatment (%) 
Total 6.96 
1 AGI + 1 BGS + 1 DPP IV + 1 SUS + 1 TGZ 0.26 
1 AGI + 1 BGS + 2 DPP IV + 3 SUS + 1 TGZ 0.26 
1 AGI + 1 BGS + 1 DPP IV + 2 SUS + 1 TGZ 0.26 
1 INS + 1 AGI + 1 BGS + 1 DPP IV + 2 SUS 0.77 
2 INS + 1 AGI + 1 BGS + 1 DPP IV + 2 SUS 0.26 
3 INS + 1 AGI + 1 BGS + 1 DPP IV + 2 SUS 0.26 
1 INS + 1 AGI + 1 BGS + 2 DPP IV + 2 SUS 0.77 
1 INS + 1 AGI + 1 BGS + 1 DPP IV + 1 SUS 3.09 
1 INS + 1 AGI + 1  BGS + 1 SUS + 1 TGZ 0.26 
1 INS + 1 AGI + 1 BGS + 2 SUS + 1 TGZ 0.26 
1 INS + 1 AGI + 1 BGS + 1 DPP IV + 1 SUS + 1 TGZ 0.26 
1 INS + 1 AGI + 1 BGS + 1 DPP IV + 2 SUS + 1 TGZ 0.26 
BGS = Biguanides, TGZ = Thioglitazones, SUS = Sulphonyl Ureas, INS = Insulins  
AGI = Alpha glucosidase inhibitors, DPP IV = DPP IV inhibitors 
COST MINIMISATION ANALYSIS OF PRESCRIBED DRUGS 
Table- 20: Cost analysis of Drug category of prescribed brands per unit  
Therapy Average Lowest 
cost (`) 
Average Highest 
cost (`) 
Difference in costs 
(`) 
AGI 4.71 13.85 9.14 
SUS 1.55 6.12 4.57 
TGZ 1.5 8.12 6.62 
INS 0.49 0.49 0 
DPPI 37.24 27.24 0 
BGS 1.15 2.48 1.33 
 
 
 
Figure 2: Cost analysis of Drug Category of prescribed brands in INR (`) 
 
 
Table- 21: Cost analysis of combination drugs of prescribed brands available in  
Market per unit 
Therapy Average Lowest 
cost (`) 
Average Highest 
cost (`) 
Difference in costs 
(`) 
AGI+BGS 6.91 8.11 1.2 
SUS+BGS 3.63 4.81 1.18 
DPP IV +BGS 20.35 20.35 0 
TGZ+BGS 4.56 5.84 1.28 
BGS+SUS+TGZ 4.98 6.63 1.65 
BGS = Biguanides, TGZ = Thioglitazones, SUS = Sulphonyl Ureas, INS = Insulins  
AGI = Alpha glucosidase inhibitors, DPP IV = DPP IV inhibitors 
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Figure 3: Cost analysis of combination drugs of prescribed brands in INR (`)  
 
Table- 22: Cost analysis of individual drug category combinations of prescribed  
Brands with market available combinations   
Therapy Lowest cost of 
individual drugs  
Lowest cost of 
combination drugs  
Difference 
AGI+BGS 5.86 6.91 1.05 
AGI+SUS 6.26 - - 
AGI+INS 5.2 - - 
BGS+DPPI 38.39 20.35 18.04 
BGS+SUS 2.70 3.63 0.93 
BGS+TGZ 2.65 4.56 1.91 
INS+BGS 1.64 - - 
INS+SUS 2.04 - - 
SUS+TGZ 3.05 - - 
BGS+  SUS+  TGZ 4.20 4.98 0.78 
BGS = Biguanides, TGZ = Thioglitazones, SUS = Sulphonyl Ureas, INS = Insulins  
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Figure 4: Cost analysis of combination drugs prescribed brands available in  
Market in INR (`) 
 
 
 
Table- 23: Annual treatment cost analysis for single drug therapy 
Therapy M.Fq. Unit cost (`) Cost/Day (`) Annual cost 
(`) 
BGS BD 1.15 2.30 840 
SUS BD 1.55 3.10 1132 
TGZ BD 1.5 3.00 1095 
INS 27 units 0.49 13.23 4830 
BGS = Biguanides, TGZ = Thioglitazones, SUS = Sulphonyl Ureas, INS = Insulins  
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Figure 5: Annual treatment cost analysis for single drug therapy in INR (`) 
 
Table- 24: Annual treatment cost analysis for 2- Drug Combination therapy 
Therapy M.Fq. Unit cost 
(`) 
Cost/ Day 
(`) 
Annual cost 
(`) 
1 AGI + 1 BGS BD 5.86 11.72 4278 
1 AGI + 1 SUS BD 6.26 12.52 4570 
1 BGS + 1 DPP IV BD 38.39 76.78 28025 
1 BGS + 1 SUS BD 2.70 5.40 1971 
1BGS + 2 SUS BD 4.25 8.50 3103 
1 BGS + 1 TGZ BD 2.65 5.30 1935 
1 AGI + 2 INS BD 31.17 35.88 13096 
1 AGI + 1 INS BD 17.94 22.65 8267 
1 BGS + 1 INS BD 14.38 15.27 5574 
1 SUS + 1 INS BD 14.78 16.33 5961 
1 INS + 2 SUS BD 16.33 19.43 7092 
3 INS + 1 SUS BD 41.24 42.79 15618 
1 SUS + 1 TGZ BD 3.05 6.10 2227 
BGS = Biguanides, TGZ = Thioglitazones, SUS = Sulphonyl Ureas, INS = Insulins  
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Figure 6: Annual treatment cost analysis for 2- Drug Combination therapy in INR (`) 
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Annual Cost of 2- Drug Combination Therapy in INR (`)
1 AGI + 1 BGS
1 AGI + 1 SUS
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3 INS + 1 SUS
1 SUS + 1 TGZ
Table- 25: Annual treatment cost analysis for 3- Drug Combination therapy 
Therapy M.Fq. Unit cost 
(`) 
Cost/Day 
(`) 
Annual 
cost (`) 
1 AGI + 1 BGS + 1 DPP IV BD 43.10 86.20 31463 
1 AGI+ 1 BGS+ 1 SUS BD 7.41 14.82 5409 
1 AGI + 1 BGS + 2 SUS BD 8.96 17.92 6541 
1 AGI + 1 BGS + 3 SUS BD 10.51 21.02 7672 
1 BGS + 1 SUS + 2 DPP IV BD 77.18 154.36 56341 
1 BGS + 1 SUS + 1 DPP IV BD 39.94 79.88 29156 
1 BGS + 1 SUS + 1 TGZ BD 4.20 8.40 3066 
1 BGS + 2 SUS + 1 TGZ BD 5.75 11.5 4198 
1 INS + 1 BGS + 1 AGI BD 19.09 24.95 9107 
2 INS + 1 BGS + 1 AGI BD 32.32 38.18 13936 
1 INS + 1 AGI + 1 SUS BD 19.49 25.75 9399 
2 INS + 1 AGI + 2 SUS BD 34.27 42.08 15359 
2 INS + 1 AGI + 1 SUS BD 32.72 38.98 14228 
3 INS + 1 AGI + 1 SUS BD 45.95 52.21 19057 
1 INS + 1 AGI + 2 SUS BD 21.04 28.85 10530 
3 INS + 1 BGS + 1 DPP IV BD 78.08 116.47 42516 
1 INS + 1 BGS + 1 SUS BD 15.93 18.63 6800 
4 INS + 1 BGS + 2 SUS BD 55.62 58.32 21287 
2 INS + 1 BGS + 2 SUS BD 30.71 34.96 12760 
2 INS + 1 BGS + 1 SUS BD 29.16 31.86 11629 
1 INS + 1 BGS + 2 SUS BD 17.48 21.73 7931 
1 INS + 1 DPP IV + 1 SUS BD 52.02 90.81 33146 
BGS = Biguanides, TGZ = Thioglitazones, SUS = Sulphonyl Ureas, INS = Insulins  
AGI = Alpha glucosidase inhibitors, DPP IV = DPP IV inhibitors 
 
 
 
 
Figure 7: Annual treatment cost analysis for 3- Drug Combination therapy in INR (`) 
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Annual cost of 3-Drug Combination Therapy in INR (`)
1 AGI + 1 BGS + 1 DPPI 1 AGI+ 1 BGS+ 1 SUS 1 AGI + 1 BGS + 2 SUS
1 AGI + 1 BGS + 3 SUS 1 BGS + 1 SUS + 2 DPPI 1 BGS + 1 SUS + 1 DPPI
1 BGS + 1 SUS + 1 TGZ 1 BGS + 2 SUS + 1 TGZ 1 INS + 1 BGS + 1 AGI
2 INS + 1 BGS + 1 AGI 1 INS + 1 AGI + 1 SUS 2 INS + 1 AGI + 2 SUS
2 INS + 1 AGI + 1 SUS 3 INS + 1 AGI + 1 SUS 1 INS + 1 AGI + 2 SUS
3 INS + 1 BGS + 1 DPPI 1 INS + 1 BGS + 1 SUS 4 INS + 1 BGS + 2 SUS
2 INS + 1 BGS + 2 SUS 2 INS + 1 BGS + 1 SUS 1 INS + 1 BGS + 2 SUS
1 INS + 1 DPPI + 1 SUS
Table- 26: Annual treatment cost analysis for 4- Drug Combination therapy 
Therapy M.Fq. Unit 
cost (`) 
Cost/da
y (`) 
Annual 
cost (`) 
1 AGI + 1 BGS + 1 DPP IV + 1 SUS BD 44.65 89.30 32595 
1 AGI + 1 BGS + 2 DPP IV  + 1 SUS BD 81.89 163.78 59780 
1 AGI + 1 BGS + 1 SUS + 1 TGZ BD 8.91 17.82 6504 
1 INS + 1 AGI + 1 BGS + 1 SUS BD 20.64 28.05 94388 
2 INS + 1 AGI + 1 BGS + 1 SUS BD 33.87 41.28 15067 
3 INS + 1 AGI + 1 BGS + 1 SUS BD 47.10 54.51 19896 
1 INS + 1 AGI + 1 BGS + 2 SUS BD 22.19 31.15 11370 
2 INS + 1 AGI + 1 BGS + 2 SUS BD 35.42 44.38 16199 
1 INS + 1 AGI + 1 BGS + 3 SUS BD 23.74 34.25 12501 
1 INS +1 SUS + 1 AGI +1 DPP IV BD 56.73 100.23 36584 
1 INS + 1 AGI + 1 SUS + 1 TGZ BD 20.99 28.75 10494 
1 INS + 1 BGS + 1 DPP IV + 1 SUS BD 53.17 93.11 33985 
1 INS + 1 BGS + 1 DPP IV+ 2 SUS BD 54.72 96.21 35117 
1 INS + 1 BGS + 2 DPP IV + 1 SUS BD 90.41 167.59 61170 
2 INS + 1 BGS + 1 DPP IV + 1 SUS BD 66.40 106.34 38814 
1 BGS + 2 SUS+ 1 TGZ + 1 INS BD 18.98 24.73 9027 
1 BGS + 3 SUS+ 1 TGZ + 1 INS BD 20.53 27.83 10158 
BGS = Biguanides, TGZ = Thioglitazones, SUS = Sulphonyl Ureas, INS = Insulins  
AGI = Alpha glucosidase inhibitors, DPP IV = DPP IV inhibitors 
 
 
 
 
 
 
 
 
Figure 8: Annual treatment cost analysis for 4- Drug Combination therapy in INR (`) 
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Annual Cost of 4-Drug combination Therapy in INR (`)
1 AGI + 1 BGS + 1 DPPI + 1 SUS 1 AGI + 1 BGS + 2 DPPI + 1 SUS
1 AGI + 1 BGS + 1 SUS + 1 TGZ 1 INS + 1 AGI + 1 BGS + 1 SUS
2 INS + 1 AGI + 1 BGS + 1 SUS 3 INS + 1 AGI + 1 BGS + 1 SUS
1 INS + 1 AGI + 1 BGS + 2 SUS 2 INS + 1 AGI + 1 BGS + 2 SUS
1 INS + 1 AGI + 1 BGS + 3 SUS 1 INS +1 SUS + 1 AGI +1 DPPI
1 INS + 1 AGI + 1 SUS + 1 TGZ 1 INS + 1 BGS + 1 DPPI + 1 SUS
1 INS + 1 BGS + 1 DPPI + 2 SUS 1 INS + 1 BGS + 2 DPPI + 1 SUS
2 INS + 1 BGS + 1 DPPI + 1 SUS 1 BGS + 2 SUS+ 1 TGZ + 1 INS
1 BGS + 3 SUS+ 1 TGZ + 1 INS
Table- 27: Annual treatment cost analysis for >4- Drug Combination therapy 
Therapy M.Fq. Unit 
cost (`) 
Cost/day 
(`) 
Annual 
cost (`) 
1 AGI + 1 BGS + 1 DPPI + 1 SUS + 1 TGZ BD 46.15 92.30 33690 
1 AGI + 1 BGS + 2 DPPI + 3 SUS + 1 TGZ BD 86.49 168.98 61678 
1 AGI + 1 BGS + 1 DPPI + 2 SUS + 1 TGZ BD 47.70 95.40 32821 
1 INS + 1 AGI + 1 BGS +1 DPP IV + 2SUS BD 59.43 105.63 38555 
2 INS + 1 AGI +1 BGS + 1 DPP IV + 2SUS BD 72.66 118.86 43384 
3 INS + 1 AGI + 1 BGS + 1 DPP IV + 2SUS BD 85.89 132.09 48213 
1 INS + 1 AGI + 1BGS + 2 DPP IV + 2 SUS BD 96.67 180.11 65740 
1 INS + 1 AGI + 1 BGS + 1 DPP IV + 1SUS BD 57.88 102.53 37422 
1 INS + 1 AGI + 1  BGS + 1 SUS + 1 TGZ BD 22.14 31.05 11333 
1 INS + 1 AGI + 1 BGS + 2 SUS + 1 TGZ BD 23.69 34.15 12465 
1 INS + 1 AGI + 1 BGS + 1 DPP IV + 1 SUS + 1 TGZ BD 59.38 105.53 38519 
1 INS + 1 AGI + 1 BGS + 1 DPP IV + 2 SUS + 1 TGZ  BD 60.93 108.63 39650 
BGS = Biguanides, TGZ = Thioglitazones, SUS = Sulphonyl Ureas, INS = Insulins  
AGI = Alpha glucosidase inhibitors, DPP IV = DPP IV inhibitors 
 
 
 
 
 
 
 
 
 
 
 Figure 9: Annual treatment cost analysis for >4- Drug Combination therapy in INR (`) 
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Annual cost of >4-Drug Combination Therapy in INR (`)
1 AGI + 1 BGS + 1 DPPI + 1 SUS + 1 TGZ 1 AGI + 1 BGS + 2 DPPI + 3 SUS + 1 TGZ
1 AGI + 1 BGS + 1 DPPI + 2 SUS + 1 TGZ 1 INS + 1 AGI + 1 BGS + 1 DPPI + 2 SUS
2 INS + 1 AGI + 1 BGS + 1 DPPI + 2 SUS 3 INS + 1 AGI + 1 BGS + 1 DPPI + 2 SUS
1 INS + 1 AGI + 1 BGS + 2 DPPI + 2 SUS 1 INS + 1 AGI + 1 BGS + 1 DPPI + 1 SUS
1 INS + 1 AGI + 1  BGS + 1 SUS + 1 TGZ 1 INS + 1 AGI + 1 BGS + 2 SUS + 1 TGZ
1 INS + 1 AGI + 1 BGS + 1 DPPI + 1 SUS + 1 TGZ 1 INS + 1 AGI + 1 BGS + 1 DPPI + 2 SUS + 1 TGZ
COST EFFECTIVENESS ANALYSIS 
Incremental Cost per Quality of Life in years gained for Single Drug therapy with 
Standard SUS (1.00 QALY; ` 1132) therapy 
Table- 28: Discounted QALY and IC with Standard therapy 
Therapy Difference in 
QALY 
Difference in 
Annual cost 
(`) 
Discounted 
QALY 
Discounted 
IC (`) 
BGS 0.1 292 0.003 8.76 
TGZ 0.26 37 0.0078 1.11 
INS 0.31 -110.91 0.0093 -3.33 
Table- 29: ICER with Standard therapy 
Therapy QALY Annual cost (`) ICER 
BGS 0.38 840 2920 
TGZ 0.22 1095 142 
INS 0.17 4829 -358 
Figure 10: ICER with Standard therapy 
 
Incremental Cost per Quality of Life in years gained for 2- Drug Combination therapy 
with  Standard 1 BGS+ 1 TGZ: (1.00 QALY; ` 1935) therapy 
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Table- 30:  Discounted QALY and IC with Standard therapy 
Therapy Difference in 
QALY 
Difference in 
Annual cost 
(`) 
Discounted  
QALY 
Discounted  
IC (`) 
AGI + BGS 0.89 -2343 0.0267 -70.29 
AGI + SUS 0.30 -2635 0.009 -79.05 
BGS + DPP IV 0.83 -26090 0.0249 -782.7 
1 BGS + 1 SUS 0.57 -36 0.0171 -1.08 
1 BGS + 2 SUS 0.48 -1168 0.0144 -350.64 
AGI + 2 INS 0.72 -11161 0.0216 -334.83 
AGI + 1 INS 0.89 -6332 0.0267 -189.96 
BGS + INS 0.89 -3639 0.0267 -109.17 
SUS + INS 0.57 -4026 0.0171 -120.78 
1 INS + 2 SUS 0.51 -5157 0.0153 -154.71 
3 INS + 1 SUS 0.58 -13683 0.0174 -410.49 
SUS + TGZ 0.27 -292 0.0081 -8.76 
BGS = Biguanides, TGZ = Thioglitazones, SUS = Sulphonyl Ureas, INS = Insulins  
AGI = Alpha glucosidase inhibitors, DPP IV = DPP IV inhibitors 
 
 
Table- 31:  ICER with Standard therapy 
Therapy QALY Annual cost (`) ICER/QALY 
AGI + BGS 0.11 4278 -2633 
AGI + SUS 0.70 4570 -8783 
BGS + DPP IV 0.17 28025 -31434 
1 BGS + 1 SUS 0.43 1971 -63 
1 BGS + 2 SUS 0.52 3103 -24350 
AGI + 2 INS 0.28 13096 -15501 
AGI + 1 INS 0.11 8267 -7114 
BGS + INS 0.11 5574 -4089 
SUS + INS 0.43 5961 -7063 
1 INS + 2 SUS 0.49 7092 -10112 
3 INS + 1 SUS 0.42 15618 -23591 
SUS + TGZ 0.73 2227 -1082 
 
Figure 11: ICER with Standard therapy 
 
Incremental Cost per Quality of Life in years gained for 3- Drug Combination therapy 
with  Standard 1 BGS + 1 SUS + 1 TGZ: (1.00 QALY; ` 3066) therapy 
Table- 32: Discounted QALY and IC with Standard therapy 
Therapy Difference 
in QALY 
Difference 
in Annual 
cost (`) 
Discounted 
QALY 
Discounted 
IC (`) 
1 AGI + 1 BGS + 1 DPP IV 0 -28397 0 -851.91 
1 AGI+ 1 BGS+ 1 SUS 0.28 -2343 0.0084 -70.29 
1 AGI + 1 BGS + 2 SUS 0.51 -3475 0.0153 -104.25 
1 AGI + 1 BGS + 3 SUS 0.51 -4606 0.0153 -138.18 
1 BGS + 1 SUS + 2 DPP IV 0.85 -53275 0.0255 -1598.25 
1 BGS + 1 SUS + 1 DPP IV 0.46 -26090 0.0138 -782.7 
1 BGS + 2 SUS + 1 TGZ 0.65 -1132 0.0195 -33.96 
1 INS + 1 BGS + 1 AGI 0 -6041 0 -181.23 
2 INS + 1 BGS + 1 AGI 0 -10870 0 -326.1 
1 INS + 1 AGI + 1 SUS 0.86 -6333 0.0258 -189.99 
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2 INS + 1 AGI + 2 SUS 0 -12293 0 -368.79 
2 INS + 1 AGI + 1 SUS 0 -11162 0 -334.86 
3 INS + 1 AGI + 1 SUS 0.89 -15991 0.0258 -479.73 
1 INS + 1 AGI + 2 SUS 0.89 -7464 0.0258 -223.92 
3 INS + 1 BGS + 1 DPP IV 0.83 -39446 0.0249 -1183.38 
1 INS + 1 BGS + 1 SUS 0.72 -3734 0.0216 -112.02 
4 INS + 1 BGS + 2 SUS 0 -18221 0 -546.63 
2 INS + 1 BGS + 2 SUS 0.41 -9694 0.0123 -290.82 
2 INS + 1 BGS + 1 SUS 0.70 -8563 0.021 -256.89 
1 INS + 1 BGS + 2 SUS 0.67 -4866 0.0201 -145.98 
1 INS + 1 DPP IV+ 1 SUS 0.89 -30080 0.0258 -902.4 
BGS = Biguanides, TGZ = Thioglitazones, SUS = Sulphonyl Ureas, INS = Insulins  
AGI = Alpha glucosidase inhibitors, DPP IV = DPP IV inhibitors 
 
Table- 33: ICER with Standard therapy 
Therapy QALY Annual cost 
(`) 
ICER/QALY 
1 AGI + 1 BGS + 1 DPP IV 1.00 31463 *** 
1 AGI+ 1 BGS+ 1 SUS 0.72 5409 -8368 
1 AGI + 1 BGS + 2 SUS 0.49 6541 -6814 
1 AGI + 1 BGS + 3 SUS 0.49 7672 -9031 
1 BGS + 1 SUS + 2 DPP IV 0.15 56341 -62677 
1 BGS + 1 SUS + 1 DPP IV 0.54 29156 -56717 
1 BGS + 2 SUS + 1 TGZ 0.35 4198 -1742 
1 INS + 1 BGS + 1 AGI 1.00 9107 *** 
2 INS + 1 BGS + 1 AGI 1.00 13936 *** 
1 INS + 1 AGI + 1 SUS 0.14 9399 -7364 
2 INS + 1 AGI + 2 SUS 1.00 15359 *** 
2 INS + 1 AGI + 1 SUS 1.00 14228 *** 
3 INS + 1 AGI + 1 SUS 0.11 19057 -18594 
1 INS + 1 AGI + 2 SUS 0.11 10530 -8679 
3 INS + 1 BGS + 1 DPP IV 0.17 42512 -47525 
1 INS + 1 BGS + 1 SUS 0.28 6800 -5186 
4 INS + 1 BGS + 2 SUS 1.00 21287 *** 
2 INS + 1 BGS + 2 SUS 0.59 12760 -23644 
2 INS + 1 BGS + 1 SUS 0.30 11629 -12233 
1 INS + 1 BGS + 2 SUS 0.33 7932 -7263 
1 INS + 1 DPP IV + 1 SUS 0.11 33146 -34977 
***- Similar QALY as per Standard with increased Incremental Cost  
BGS = Biguanides, TGZ = Thioglitazones, SUS = Sulphonyl Ureas, INS = Insulins  
AGI = Alpha glucosidase inhibitors, DPP IV = DPP IV inhibitors 
 
 
 
Figure 12: ICER with Standard therapy 
 
 
 
-70000
-60000
-50000
-40000
-30000
-20000
-10000
0
0 0.2 0.4 0.6 0.8 1 1.2
In
cr
e
m
e
n
ta
l c
o
st
QALY
ICER of 3- Drug Combination Therapy
 Incremental Cost per Quality of Life in years gained for 4- Drug Combination therapy 
with  Standard 1 INS + 1 BGS+ 1 DPPI + 1 SUS (1.00 QALY; ` 33985) therapy 
Table- 34:  Discounted QALY and IC with Standard therapy 
Therapy Difference 
in  
QALY 
Difference 
in Annual 
cost (`) 
Discounted 
QALY 
Discounted 
IC (`) 
1 AGI + 1 BGS + 1 DPP IV + 1SUS 0.61 1390 0.0183 41.7 
1 AGI + 1 BGS + 2 DPP IV + 1SUS 0.77 -25795 0.0231 -773.85 
1 AGI + 1 BGS + 1 SUS  + 1 TGZ 0.64 27481 0.0192 824.43 
1 INS + 1 AGI + 1 BGS + 1 SUS 0.36 -60403 0.0108 -1812.09 
2 INS + 1 AGI + 1 BGS + 1 SUS 0.87 18918 0.0261 567.54 
3 INS + 1 AGI + 1 BGS + 1 SUS 0.75 14089 0.0225 422.67 
1 INS + 1 AGI + 1 BGS + 2 SUS 0.59 22615 0.0177 678.45 
2 INS + 1 AGI + 1 BGS + 2 SUS 0.89 17786 0.0267 533.58 
1 INS + 1 AGI + 1 BGS + 3 SUS 0.44 21484 0.0132 644.52 
1 INS +1 SUS + 1 AGI + 1 DPP IV 0 -2599 0 -77.97 
1 INS + 1 AGI + 1 SUS + 1TGZ 0.89 23491 0.0267 704.73 
1 INS + 1 BGS + 1 DPP IV + 2 SUS 0.56 -1132 0.0168 -33.96 
1 INS + 1 BGS + 2 DPP IV + 1 SUS 0.89 -27185 0.0267 -815.55 
2 INS + 1 BGS + 1 DPP IV + 1 SUS 0 -4829 0 -144.87 
1 BGS + 2 SUS + 1 TGZ + 1 INS 0.78 24958 0.0234 748.74 
1 BGS + 3 SUS + 1 TGZ + 1 INS 0.39 23827 0.0117 714.81 
BGS = Biguanides, TGZ = Thioglitazones, SUS = Sulphonyl Ureas, INS = Insulins  
AGI = Alpha glucosidase inhibitors, DPP IV = DPP IV inhibitors 
 
 
 
 
 
 
 
Table- 35: ICER with Standard therapy 
Therapy QALY Annual cost 
(`) 
ICER/QALY 
1 AGI + 1 BGS + 1 DPP IV + 1SUS 0.39 32595 2279 
1 AGI + 1 BGS + 2 DPP IV + 1SUS 0.23 59780 -33500 
1 AGI + 1 BGS + 1 SUS + 1 TGZ 0.36 6504 42939 
1 INS + 1 AGI + 1 BGS + 1 SUS 0.64 94388 -167786 
2 INS + 1 AGI + 1 BGS + 1 SUS 0.13 15067 21745 
3 INS + 1 AGI + 1 BGS + 1 SUS 0.25 19896 18785 
1 INS + 1 AGI + 1 BGS + 2 SUS 0.41 11370 38330.51 
2 INS + 1 AGI + 1 BGS + 2 SUS 0.11 16199 19984 
1 INS + 1 AGI + 1 BGS + 3 SUS 0.56 12501 48827 
1 INS +1 SUS + 1 AGI + 1 DPP IV 1.00 36584 *** 
1 INS + 1 AGI + 1 SUS + 1TGZ 0.11 10494 26394 
1 INS + 1 BGS + 1 DPP IV + 2 SUS 0.44 35117 -2021 
1 INS + 1 BGS + 2 DPP IV + 1 SUS 0.11 61170 -30545 
2 INS + 1 BGS + 1 DPP IV + 1 SUS 1.00 38814 *** 
1 BGS + 2 SUS + 1 TGZ + 1 INS 0.22 9027 31997 
1 BGS + 3 SUS + 1 TGZ + 1 INS 0.61 10158 61095 
***- Similar QALY as per Standard with increased Incremental Cost  
BGS = Biguanides, TGZ = Thioglitazones, SUS = Sulphonyl Ureas, INS = Insulins  
AGI = Alpha glucosidase inhibitors, DPP IV = DPP IV inhibitors 
 
 
 
 
 
 
 
 
 
Figure 13: ICER with Standard therapy 
 
 
Incremental Cost per Quality of Life in years gained for >4- Drug Combination therapy 
with Standard 1 AGI+ 1 BGS+ 1 DPPI+ 2 SUS+ 1 TGZ (1.00 QALY; ` 32821) therapy  
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Table- 36:  Discounted QALY and IC with Standard therapy 
Therapy Difference 
in 
QALY 
Difference 
In Annual 
cost (`) 
Discounted 
QALY 
Discounted 
IC (`) 
1 AGI+ 1 BGS+ 1 DPP IV+ 1 SUS + 
1 TGZ 
0.89 -869 0.0267 -26.07 
1 AGI+ 1 BGS+ 2 DPP IV+ 3 SUS + 
1 TGZ 
0.83 -28857 0.0249 -865.71 
1 INS+ 1 AGI + 1BGS + 1 DPP IV + 
2 SUS 
0.59 -5734 0.0177 -172.02 
2 INS+ 1 AGI + 1BGS + 1 DPP IV + 
2 SUS 
0.34 -10563 0.0102 -316.89 
3 INS+ 1 AGI + 1BGS + 1 DPP IV + 
2 SUS 
0.89 -15392 0.0267 -461.76 
1 INS+ 1 AGI + 1BGS + 2 DPP IV + 
2 SUS 
0.35 -32919 0.0105 -987.57 
1 INS+ 1 AGI + 1BGS + 1 DPP IV + 
1 SUS 
0.61 -4603 0.0183 -138.09 
1 INS+ 1 AGI+ 1 BGS+ 1 SUS + 1 
TGZ 
0.60 21488 0.018 644.64 
1 INS+ 1 AGI+ 1 BGS+ 2 SUS + 1 
TGZ 
0.89 20356 0.0267 610.68 
1 INS+1 AGI+1 BGS+1 DPP IV +1 
SUS +1 TGZ 
0 -5698 0 -170.94 
1 INS+1 AGI+1 BGS+1 DPP IV + 2 
SUS+1 TGZ 
0.89 -6829 0.0267 -204.87 
BGS = Biguanides, TGZ = Thioglitazones, SUS = Sulphonyl Ureas, INS = Insulins  
AGI = Alpha glucosidase inhibitors, DPP IV = DPP IV inhibitors 
 
 
 
 
 
 
 
Table- 37: ICER with Standard therapy 
Therapy QALY Annual cost 
(`) 
ICER/QALY 
1 AGI+ 1 BGS+ 1 DPP IV+ 1 SUS+ 
1 TGZ 
0.11 33690 -976 
1 AGI+ 1 BGS+ 2 DPP IV + 3 SUS+ 
1 TGZ 
0.17 61678 -34768 
1 INS+ 1 AGI + 1BGS + 1 DPP IV + 
2 SUS 
0.41 38555 -9719 
2 INS+ 1 AGI + 1BGS + 1 DPP IV + 
2 SUS 
0.34 43384 -31068 
3 INS+ 1 AGI + 1BGS + 1 DPP IV+ 
2 SUS 
0.11 48213 -17294 
1 INS+ 1 AGI + 1BGS + 2 DPP IV + 
2 SUS 
0.65 65740 -94054 
1 INS+ 1 AGI + 1BGS + 1 DPP IV + 
1 SUS 
0.39 37424 -7546 
1 INS+ 1 AGI+ 1 BGS+ 1 SUS+ 1 
TGZ 
0.40 11333 35813 
1 INS+ 1 AGI+ 1 BGS+ 2 SUS+ 1 
TGZ 
0.11 12465 22872 
1 INS + 1 AGI + 1 BGS+ 1 DPP IV 
+1 SUS+1 TGZ 
1.00 38519 *** 
1 INS+1 AGI+1 BGS+1 DPP IV +2 
SUS+1 TGZ 
0.11 39650 -7673 
***- Similar QALY as per Standard with increased Incremental Cost  
BGS = Biguanides, TGZ = Thioglitazones, SUS = Sulphonyl Ureas, INS = Insulins  
AGI = Alpha glucosidase inhibitors, DPP IV = DPP IV inhibitors 
 
 
 
 
 
 
Figure 14: ICER with Standard therapy 
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Results & Discussion 
 
 
 
 
VII. RESULTS AND DISCUSSION 
Diabetes is a chronic disease that requires continuing medical care to reduce 
the risk of long term complications. Self management education to prevent acute 
complications may improve patient well being; still the pharmaceutical management has an 
inevitable role. An economical analysis of antidiabetic agents has been performed in societal 
perspective to assess and evaluate those pharmaceuticals.  
A total of 421 subjects were randomly enrolled in the study for a period of 12 
months. Of these, 12 subjects (3.33% of enrollees) were excluded from survey regarding the 
prevalence of diabetes, and 33 (7.84% of enrollees) were excluded from economic analysis, 
because they moved away during the follow-up period. They were separately analyzed 
according to the age wise and duration wise distribution of diabetes. Table 1 
Age wise distribution of diabetes was evaluated from a total of 407 patients 
enrolled that   included 225 men (55.28%) and 182 women (44.72%). A sum of 137  patients 
(33.66%) present within the age group 51-60 years having an average duration of 6 years of 
diabetes and reaches a higher duration of 11-15 under 71-80 years of age which is similar to 
the data observed by Esposti et al.59 and Bhatti et al.18.   A higher population of 81.33% 
regular non-vegetarians was identified than 11.79% of patients were vegetarians falling under 
the age group 51-60 years with 27.52% and 4.42% respectively. Weight loss was reported by 
43.98% of patients compared to 9.09% patients with weight gain with an increased level of 
15.48 % and 3.19% respectively under the age group 51-60 years. Patients with higher Body 
Mass Index (BMI >25 Kg/m2) were present in the age group 41-80 years out of which 51-60 
years age group patients shown obese with a higher average BMI of 26.19 Kg/m2. It was 
found that 14.25 % of tobacco users (4.91% under age group 41-50) and 13.51% of 
alcoholics were present with a significantly lower rate of physical activity 56.76 % of 
sedentary (19.90% under 51-60 years) and 5.41% pensioners (2.21 % under 61-70 years) than 
28.99% active patients (11.06 % under 41-50 years) that complies with the report of Bhatti et 
al.18 Table 2 & 3 
Duration wise distribution pattern of diabetes was assessed from a population 
of 407 patients comprising 222 men (54.55%) and 185 women (45.45%). A total of 162 
(39.80%) were present with a duration of 1-5 years, possessing an average age group of 57 
years with increased number of patients age group of 51-60 under 1-5 years of duration 
which is parallel to the data observed by Esposti et al.59, and Bhatti et al18. A total of 10.57% 
vegetarians were over taken by 82.56% non-vegetarians with a group of 3.69 % under 6-10 
years and 33.42% under 1-5 years of duration. Patients identified under duration of diabetes 
1-5 years were noticed with 14% of weight loss and 4.67 % of weight gain. As a whole, 
weight gain was exercised by much less patients 8.60% than weight loss 44.47%. A higher 
number of obese patients with an average Body Mass Index (BMI) of 31.24 Kg/m2 had 
duration of diabetes especially between 21-25 years, from a wide range of above 11 years. 
Tobacco users and alcoholics were present as 14.50% and 12.78% respectively which was 
been identified with a large population of 7.62% tobacco users and 14.5% alcoholics with a 
duration of 1-5 years. 30.47% of active diabetic patients (14.5 % under 1-5) were present, 
which was much less than 58.72% of sedentary (20.64% under 1-5) and 5.65% of pensioners 
(1.47 % under 1-15) similar to the figures provided by Bhatti et al18. Table 4 & 5 
Microvascular complications were found very common in patients within the 
age group 51-60 years with 15.97% of Retinopathy, 7.62% of Foot ulcer, 14.50% of 
Nephropathy and 18.67% of Neuropathy. At the same time these complications are more 
persistent during 1-5 years of duration of diabetes, with a rate of retinopathy (18.43%), Foot 
ulcer (7.86%), nephropathy (17.20%), and neuropathy (19.90%). Among the macro vascular 
diseases, peripheral vascular disease is more common with duration of 6-10 years (0.98%). 
Other macro vascular complications are common with 1-5 years of duration of diabetes were 
hypertension (18.92%), Dyslipidemia (9.34%), and Cardio vascular diseases (2.95%). 
Hypertension leads foremost macro vascular complications of 16.22% within the age group 
61-70 years. But, Dyslipidemia is a major disorder which shows its increased prevalence of 
7.37% among the age group 51-70 years. Cardio vascular complications has its more 
prevalence within the age group 51-60 years, the same do the peripheral vascular diseases 
even with a small percentage of 0.98. Table 6-9 
With ongoing treatment,  no suffering was mostly experienced by patients 
within the age group 51-60 years (23.59%) and duration of 1-5 years (24.82%), Mild and 
moderate levels of suffering is faced by patients within the age group 41-50 years (6.14% and 
1.47% respectively ) along with a duration of 1-5 years (8.85 and 1.97% respectively ). 
Severe suffering levels were noticed by patients with age group 71-80 years and 11-15 years 
of duration (0.25% each). Mild to moderate  physical activity restriction was higher among 
patients with 51-60 years of age (13.76% and 4.18% respectively)  and with a duration of 1-5 
years (14.74% and 6.14% respectively) but no restriction to physical activity was noticed in 
patients with in the age group 51-60 years (10.32%)and duration 1-5 years (12.04%). Severe 
restriction on physical activity was showed by patients among the age group 41-50 years 
(2.95 %) and with duration of 1-5 years (2.7%). Table 10 - 13 
Cost analysis is performed by taking into account the direct costs of 
antidiabetic drugs and evaluated at MIMS-Asia purchase prices. Costs were expressed as 
overall and average values. The currency reference was the Indian Rupees (`). Cost 
minimization analysis was performed using the evaluated purchase prices for each type of 
therapy provided to the patients. Cost effectiveness analysis was performed for each therapy 
provided based on the reports obtained from cost minimization analysis.  
A total of 388 patients (92.16% of enrollees) were provided treatment with 
single and combining several classes of antidiabetic drugs at enrollment. Single drug therapy 
was provided to 8.76% of patients, 2- Drug combination therapy to 38.92% of patients, 3- 
Drug combination therapy to 30.15% of patients, 4- Drug combination therapy to 15.21% of 
patients, and >4- Drug combination therapy to 6.96% of patients. The average age and 
duration of the patients received each type of therapy is given in Table 15. 
Biguanides were the class of drug most commonly prescribed for monotherapy 
(8.76%), followed by Sulphonyl ureas (2.32%), Insulins (0.52%), and Thioglitazones 
(0.26%). Patient age and duration of diabetes by class of drug prescribed at enrollment are 
presented in Table 15. 
Therapy with combination of two drugs was provided to 151 patients 
(38.92%) in which patients fall within the age group 41-50 years with duration of 6-10 years 
of diabetes. The increased numbers of patients (27.84%) were treated with a combination of 
one Biguanide and one Sulphonyl ureas with age group 51-60 years and duration of 6-10 
years followed by 2.32% each of the patients with one Biguanide plus two Sulphonyl ureas 
and one Sulphonyl ureas plus 27  units of Insulin, 1.03% each of the patients with one Alpha 
Glucosidase inhibitor plus 2 X 27  units of Insulin and  one Alpha Glucosidase inhibitor plus 
one Sulphonyl ureas, 0.77% each of the patients with one Alpha Glucosidase inhibitor plus 
27  units of Insulin, 0.52% each of the patients with one Biguanide plus one Thioglitazone 
and one Sulphonyl ureas plus 3 X 27  units of Insulin and one Sulphonyl ureas plus one 
Thioglitazone, 0.26% each of the patients with one Biguanide plus one DPP IV inhibitor, one 
Biguanide plus 27  units of Insulin, one Sulphonyl ureas plus 2 X 27  units of Insulin and  one 
Alpha Glucosidase inhibitor plus one Biguanide. Table 16 
Combination therapy of 3 drugs was given to 117 patients (30.15%) with 
duration of 11-15 years and age group of 51-60 years. The higher numbers of patients 
(7.99%) were treated with a combination of one Biguanide plus one Sulphonyl ureas  and 27 
units of Insulin with an average age group of 51-60 years and duration of 6-10 years, 
followed by 6.7% each of the patients with one Alpha Glucosidase inhibitor plus one 
Biguanide plus one Sulphonyl ureas, 4.12% each of the patients with one Biguanide plus one 
Sulphonyl ureas plus one DPP IV inhibitor, 2.32% each of the patients with one Alpha 
Glucosidase inhibitor, one Biguanide and two Sulphonyl ureas, 1.55% each of the patients 
with one Biguanide plus two Sulphonyl ureas plus one Thioglitazone, 1.29% each of the 
patients with one Biguanide plus one Sulphonyl ureas plus one Thioglitazone, 0.77% each of 
the patients with one Biguanide plus one Sulphonyl ureas plus two DPP IV inhibitors, 27 
units of Insulin plus one Alpha Glucosidase inhibitor plus one Sulphonyl ureas, and 27 units 
of Insulin plus one Biguanide plus two Sulphonyl ureas,  0.52% each of the patients with 2 X 
27 units of Insulin plus one Alpha Glucosidase inhibitor plus one Sulphonyl ureas, 2 X 27 
units of insulin plus one Biguanide plus one Sulphonyl ureas, 0.26% each of the patients with 
one Alpha Glucosidase inhibitor plus one Biguanide plus one DPP IV inhibitor, one Alpha 
Glucosidase inhibitor plus one Biguanide plus three Sulphonyl ureas, 2 X 27 units of Insulin 
plus one Alpha Glucosidase inhibitor plus two Sulphonyl ureas, 27 units of Insulin plus one 
Biguanide plus one Alpha Glucosidase inhibitor, 2 X 27 units of Insulin plus one Biguanide 
plus one Alpha Glucosidase inhibitor, 3 X 27 units of Insulin plus one Alpha Glucosidase 
inhibitor plus one Sulphonyl ureas, 27 units of Insulin plus one Alpha Glucosidase inhibitor 
plus two Sulphonyl ureas, 3 X 27 units of Insulin plus one Alpha Glucosidase inhibitor plus 
one DPP IV inhibitor, 4 X 27 units of Insulin plus one Biguanide plus two Sulphonyl ureas, 2 
X 27 units of Insulin plus one Biguanide plus two Sulphonyl ureas and 27 units of Insulin 
plus one DPP IV inhibitors plus one Sulphonyl ureas. Table 17 
The 4-drug combination therapy was provided to 59 patients (15.21%) with an 
age rgroup average of 51-60 years and duration of 6-10 years. A large population (2.84%) 
was treated with a combination of one Alpha Glucosidase inhibitor plus one Biguanide plus 
one DPP IV inhibitor plus one Sulphonyl ureas with an age group of 51-60 years and an 
average duration of 6-10 years followed by 2.58% each of the patients with 27 units of 
insulin plus one Alpha Glucosidase inhibitors plus one Biguanide plus one Sulphonyl ureas, 
1.55% each of the patients with 27 units of Insulin plus one Biguanide plus one DPP IV 
inhibitor plus two Sulphonyl ureas, 1.29% each of the patients with 3 X 27 units of Insulin 
plus one Alpha glucosidase inhibitor plus one Biguanide plus one Sulphonyl ureas, 1.03% 
each of the patients with one Alpha Glucosidase inhibitor plus one Biguanide plus two DPP 
IV inhibitors plus one Sulphonyl ureas and 27 units of Insulin plus one Alpha glucosidase 
inhibitor plus one Biguanide plus two Sulphonyl ureas, 0.77% each of the patients with one  
Alpha Glucosidase inhibitor plus one Biguanide plus one Sulphonyl ureas plus one 
Thioglitazone and 2 X 27 units of Insulin plus one Alpha glucosidase inhibitor plus one 
Biguanide plus one Sulphonyl ureas, 0.52% each of the patients with 2 X 27 units of Insulin 
plus one Alpha glucosidase inhibitor plus one Biguanide plus two Sulphonyl ureas, 27 units 
of Insulin plus one Alpha glucosidase inhibitor plus one Biguanide plus three Sulphonyl 
ureas, 27 units of Insulin plus one Alpha glucosidase inhibitor plus one Sulphonyl ureas plus 
one DPP IV inhibitors and 27 units of Insulin plus one Biguanide plus one DPP IV inhibitor 
plus one Sulphonyl ureas, 0.26% each of the patients with 27 units of Insulin plus one Alpha 
Glucosidase inhibitor plus one Sulphonyl ureas plus one Thioglitazone, 27 units of Insulin 
plus one Biguanide plus two DPP IV inhibitors plus one Sulphonyl ureas, 2 X 27 units of 
Insulin plus one Biguanide plus two DPP IV inhibitors plus one Sulphonyl ureas, one 
Biguanide plus two Sulphonyl ureas plus one Thioglitazone plus 27 units of Insulin and one 
Biguanide plus three Sulphonyl ureas plus one Thioglitazone plus 27 units of Insulin. Table 
18 
Combination of >4 drugs was provided for (6.96%) of patients with an age 
group of 51-60 years and with duration of 6-10 years. A population of 3.09% of patients was 
treated with a combination of 5 drugs of 27 units of insulin plus one Alpha Glucosidase 
inhibitor plus one Biguanide plus one DPP IV inhibitor plus one Sulphonyl ureas with an 
average age group of 51-60 years and duration of 11-15 years followed by 0.77 % each of the 
patients with 27 units of Insulin plus one Alpha Glucosidase inhibitor plus one Biguanide 
plus one DPP Inhibitor plus two Sulphonyl ureas and 27 units of Insulin plus one Alpha 
Glucosidase inhibitor plus one Biguanide plus two DPP Inhibitors plus two Sulphonyl ureas, 
0.26% each of the patients with one Alpha Glucosidase inhibitor plus one Biguanide plus one 
DPP Inhibitor plus one Sulphonyl ureas plus one Thioglitazone, one Alpha Glucosidase 
inhibitor plus one Biguanide plus two DPP Inhibitors plus three Sulphonyl ureas plus one 
Thioglitazone, one Alpha Glucosidase inhibitor plus one Biguanide plus one DPP Inhibitor 
plus two Sulphonyl ureas plus one Thioglitazones, 2 X 27 units of Insulin plus one Alpha 
Glucosidase inhibitor plus one Biguanide plus one DPP Inhibitor two Sulphonyl ureas, 3 X 
27 units of Insulin plus one Alpha Glucosidase inhibitor plus one Biguanide plus one DPP 
Inhibitor two Sulphonyl ureas, 27 units of Insulin plus one Alpha Glucosidase inhibitor plus 
one Biguanide plus one Sulphonyl ureas plus one Thioglitazone, 27 units of Insulin plus one 
Alpha Glucosidase inhibitor plus one Biguanide plus two Sulphonyl ureas plus one 
Thioglitazone, 27 units of Insulin plus one Alpha Glucosidase inhibitor plus one Biguanide 
plus one Sulphonyl ureas plus one Thioglitazone plus one DPP IV inhibitor and 27 units of 
Insulin plus one Alpha Glucosidase inhibitor plus one Biguanide plus two Sulphonyl ureas 
plus one Thioglitazone plus one DPP IV inhibitors. Table 19  
Cost minimization analysis was performed among each class of the drug in 
single drug prescription and for each type of combinations of drugs available in market which 
aids in combination therapy of the drugs which fall under the prescribed brands of drugs. 
Among the prescribed brands Lowest cost per unit of drug was Biguanides (` 1.15) and 
highest was for DPP IV inhibitors (` 37.24). The cost differences among the prescribed brand 
were more prominent among the drug under the class of Alpha Glucosidase inhibitors (` 
9.14). Among the combination drugs available Lowest cost per unit was obtained for 
Sulphonyl ureas plus Biguanides (` 3.63) while the highest was for Biguanides plus DPP IV 
inhibitors (` 20.35). The increased cost variation among the prescribed brands was for a 
combination of Biguanides plus Sulphonyl ureas plus Thioglitazones. Mean daily dose taken 
by each patient was 2 doses per day as an average of prescribed frequency and 27 units of 
insulin were consumed by each patient per day for the entire year. Table 20 & 22 
Annual treatment cost was calculated for each class of drug prescribed drug 
for monotherapy. The lowest annual cost was found to be spend by patients taking 
Biguanides (` 840), followed by Thioglitazones (` 1,095), Sulphonyl ureas (` 1,132) and 
Insulins (` 4,830). Table 23 
Annul treatment cost for 2-drug combination therapy of prescribed drug was 
more when compared to single drug therapy. The lowest cost was spent by the population 
consuming one Biguanide plus one Thioglitazone (`1,935) followed by one Biguanide plus 
one Sulphonyl ureas (` 1,971), one Sulphonyl ureas plus one Thioglitazone (` 2,227), one 
Biguanide plus two Sulphonyl ureas (` 3,103), one Alpha Glucosidase inhibitor plus one 
Biguanide (` 4,278), one Alpha Glucosidase inhibitor plus one Sulphonyl ureas (` 4,570), 
one Biguanide plus 27 units of Insulin (` 5,574), one Sulphonyl ureas plus 27 units of Insulin 
(` 5,961), 27 units of Insulin plus two Sulphonyl ureas (` 7,092), one Alpha Glucosidase 
inhibitor plus 27 units of Insulin (` 8,267), one Alpha Glucosidase inhibitor plus 27 X 2 units 
of Insulin (` 13,096), one Sulphonyl ureas plus 27 X 3 units of Insulin (` 15,618) and one 
Biguanide plus one DPP IV inhibitors (` 28,025). Table 24 
Annul treatment cost for 3-drug combination therapy of prescribed drug was 
more when compared to single drug therapy and 2- drug combination therapy. The lowest 
cost was spent by the population consuming one Biguanide plus one Sulphonyl ureas plus 
one Thioglitazone (` 3,066) followed by one Biguanide plus two Sulphonyl ureas plus one 
Thioglitazone (` 4,198), one Alpha Glucosidase inhibitor plus one Biguanide  plus one 
Sulphonyl ureas (` 5,409), one Alpha Glucosidase inhibitor plus one Biguanide  plus two 
Sulphonyl ureas (` 6,541), one Biguanides plus 27 units of Insulin plus one Sulphonyl ureas 
(` 6,800), one Alpha Glucosidase inhibitor plus one Biguanide  plus three Sulphonyl ureas (` 
7,672), one Biguanide plus 27 units of Insulin plus two Sulphonyl ureas (` 7,931), one Alpha 
Glucosidase inhibitor plus 27 units of Insulin plus one Biguanide  (` 9,107), one Alpha 
Glucosidase inhibitor plus 27 units of Insulin plus one Sulphonyl ureas (` 9,399), one Alpha 
Glucosidase inhibitor plus 27 units of Insulin plus two Sulphonyl ureas (` 10,530), one 
Biguanide plus 27 X 2 units of Insulin plus one Sulphonyl ureas (` 11,629), one Biguanide 
plus 27 X 2 units of Insulin plus two Sulphonyl ureas (` 12,760), 27 X 2 units of Insulin plus 
one Biguanide plus one Alpha Glucosidase inhibitor (` 13,936), 27 X 2 units of Insulin plus 
one Alpha Glucosidase inhibitor plus one Sulphonyl ureas (` 14,228), 27 X 2 units of Insulin 
plus one Alpha Glucosidase inhibitor plus two Sulphonyl ureas (` 15,359), 27 X 3 units of 
Insulin plus one Alpha Glucosidase inhibitor plus one Sulphonyl ureas (` 19,057), 27 X 4 
units of Insulin plus one Biguanide plus two Sulphonyl ureas (` 21,287), one Biguanide plus 
one Sulphonyl ureas plus one DPP IV inhibitor (` 29,156), one Biguanide plus one DPP IV 
inhibitor plus one Alpha Glucosidase inhibitor (` 31,463), 27 units of Insulin plus one 
Sulphonyl ureas plus one DPP IV inhibitor (` 33,146), 27 units of Insulin plus one Biguanide 
plus one DPP IV inhibitor (` 42,516) and one Biguanide plus one Sulphonyl ureas plus two 
DPP IV inhibitors (` 56,341). Table 25 
In annul treatment cost for 4-drug combination therapy, the lowest cost was 
spent by the population consuming one Alpha Glucosidase inhibitor plus one Biguanide plus 
one Sulphonyl ureas plus one Thioglitazone (` 6,504) followed by 27 units of Insulin plus 
one Biguanide plus two Sulphonyl ureas plus one Thioglitazone (` 9,027), 27 units of Insulin 
plus one Biguanide plus three Sulphonyl ureas plus one Thioglitazone (` 10,158), 27 units of 
Insulin plus one Alpha Glucosidase inhibitor plus one Sulphonyl ureas plus one 
Thioglitazone (` 10,494), 27 units of Insulin plus one Alpha Glucosidase inhibitor one 
Biguanide plus two Sulphonyl ureas (` 11,370), 27 units of Insulin plus one Alpha 
Glucosidase inhibitor one Biguanide plus three Sulphonyl ureas (` 12,501), 27 X 2 units of 
Insulin plus one Alpha Glucosidase inhibitor one Biguanide plus one Sulphonyl ureas (` 
15,067), 27 X 2  units of Insulin plus one Alpha Glucosidase inhibitor one Biguanide plus 
two Sulphonyl ureas (` 16,199), 27 X 3 units of Insulin plus one Alpha Glucosidase inhibitor 
plus one Biguanide plus one Sulphonyl ureas (` 19,896), one Alpha Glucosidase inhibitor 
one Biguanide plus one Sulphonyl ureas plus one DPP IV inhibitor (` 32,595), 27 units of 
Insulin plus one Biguanide plus one Sulphonyl ureas plus one DPP IV inhibitor (` 33,985), 
27 units of Insulin plus one Biguanide plus two Sulphonyl ureas plus one DPP IV inhibitor (` 
35,117), 27 units of Insulin plus one Sulphonyl ureas plus one Alpha Glucosidase inhibitor 
plus one DPP IV inhibitor (` 36,584), 27 X 2 units of Insulin plus one Biguanide plus one 
Sulphonyl ureas plus one DPP IV inhibitor (` 38,814), one Alpha Glucosidase inhibitor plus 
one Biguanide plus two DPP IV inhibitors plus one Sulphonyl ureas (` 59,780), 27 units of 
Insulin plus one Biguanide plus two DPP IV inhibitors plus one Sulphonyl ureas (` 61,170) 
and 27 units of Insulin plus one Alpha Glucosidase inhibitor plus one Biguanides plu one 
Sulphonyl ureas (`  94,388). Table 26 
In annul treatment cost for >4- drug combination therapy; the lowest cost was 
spent by the population consuming one Alpha Glucosidase inhibitor plus one Biguanide plus 
one DPP IV inhibitors one Sulphonyl ureas plus one Thioglitazone (` 11,333) followed by 27 
units of Insulin plus one Alpha Glucosidase inhibitor plus one Biguanide plus one Sulphonyl 
ureas plus one Thioglitazone (` 12,465), one Alpha Glucosidase inhibitor plus one Biguanide 
plus one DPP IV inhibitor plus two Sulphonyl ureas plus one Thioglitazone (` 32,821), one 
Alpha Glucosidase inhibitor plus one Biguanide plus one DPP IV inhibitor plus one 
Sulphonyl ureas plus one Thioglitazone (` 33,690), 27 units of Insulin plus one Alpha 
Glucosidase inhibitor plus one Biguanide plus one DPP IV inhibitor plus two Sulphonyl 
ureas (` 37,422), 27 units of Insulin plus one Alpha Glucosidase inhibitor plus one 
Biguanides plus one DPP IV inhibitors plus one Sulphonyl ureas plus one Thioglitazone (` 
38,519), 27 units of Insulin plus one Alpha Glucosidase inhibitor plus one Biguanide plus one 
DPP IV inhibitor plus two Sulphonyl ureas (` 38,555), 27 units of Insulin plus one Alpha 
Glucosidase inhibitor plus one Biguanide plus one DPP IV inhibitor plus two Sulphonyl 
ureas plus one Thioglitazone (` 39,650), 27 X 2 units of Insulin plus one Alpha Glucosidase 
inhibitor plus one Biguanide plus one DPP IV inhibitor plus two Sulphonyl ureas (` 43,384), 
27 X 3 units of Insulin plus one Alpha Glucosidase inhibitor plus one Biguanide plus one 
DPP IV inhibitor plus two Sulphonyl ureas (` 48,213), one Alpha Glucosidase inhibitor plus 
one Biguanide plus two DPP IV inhibitors plus three Sulphonyl ureas plus one Thioglitazone 
(` 61,678) and 27 units of Insulin plus one Alpha Glucosidase inhibitor plus one Biguanide 
plus two DPP IV inhibitors plus two Sulphonyl ureas (` 65,740). Table 27 
Cost effectiveness analysis was performed for each type of therapy taking the 
drug which elicited a higher Quality Adjusted Life in years (QALY). The negative costs 
indicates the increased incremental cost already spend by the patient to achieve the QALY 
similar to the standard drug or the QALY which is still less than that of the standard, while 
the positive cost estimates the incremental cost that has to be invested to obtain the QALY 
similar to that of the QALY.  
Sulphonyl ureas have shown to provide a higher QALY (1.00) with lower 
annual cost ` 840, in the study period which has been taken as a standard to analyze the CE 
of other mono therapy. Patients using Biguanides and Thioglitazones mono therapy have to 
pay an incremental cost of ` 2,920 /QALY and ` 142 /QALY to gain the increased QALY 
similar to that of Sulphonyl ureas. In case of insulin monotherapy the Sulphonyl ureas will 
dominate in both QALY and less amount paid per year. Table 29 
The standard for 2-drug therapy was combination of each dose of one 
Bigunide and one Thioglitazone that has shown to have an increased QALY (1.00) with an 
annual cost of ` 1,935. The standard combination was found to the dominant with less annual 
cost than any other drug combinations of one Biguanide plus one Sulphonyl ureas (-` 63 / 
QALY), one Sulphonyl ureas plus one Thioglitazone (-` 1,082 / QALY), one Biguanide plus 
one Alpha Glucosidase inhibitor (-` 2633 / QALY), 27 units of insulin plus one Biguanide (-
` 4089 INR/ QALY), 27 units of insulin plus one Sulphonyl ureas (-` 7,063 / QALY), 27 
units of insulin plus one Alpha Glucosidase inhibitor (-` 7,114/ QALY), one Alpha 
Glucosidase inhibitor plus one Sulphonyl ureas (-` 8,783 / QALY), 27 units of insulin plus 
one Sulphonyl ureas (-` 10112 / QALY), 27 X 2 units of insulin plus one Alpha Glucosidase 
inhibitor  (-`15,501 / QALY), 27 X 3 units of insulin plus one Sulphonyl ureas (-` 23,591 
INR/ QALY), one Biguanide plus two Sulphonyl ureas ( -` 24,350 / QALY) and one 
Biguanide plus one DPP IV inhibitor (-` 31,434 / QALY). Table 31 
A combination of one Biguanide plus one Sulphonyl ureas plus one  
Thioglitazone with a QALY of 1.00 and ` 3066 as total annual cost which stands the top 
among all the 3- drug combinations in case of discounted Incremental cost also. The standard 
combination had a QALY which was similar to other 6 drug combinations prescribed, but 
their increased discounted incremental cost than the standard can have an economical impact 
on the use of those drugs that includes 27 units of insulin plus one Biguanide plus one Alpha 
Glucosidase inhibitor (-` 181.23) 27 X 2 units of insulin plus one Biguanide plus one Alpha 
Glucosidase inhibitor (-` 326.1) 27 X 2 units of insulin plus one Alpha Glucosidase inhibitor 
plus one Sulphonyl ureas (-` 334.86) 27 X 2 units of insulin plus one Alpha Glucosidase 
inhibitor plus two Sulphonyl ureas (-` 368.79) one Biguanide plus two Sulphonyl ureas plus 
27 X 4 units of insulin (-` 546.63) and one Alpha Glucosidase inhibitor plus one DPP IV 
inhibitors plus one Biguanide (-` 851.91). Incremental cost effectiveness ratio of the other 
drugs in which the standard dominates includes one Biguanide plus two Sulphonyl ureas plus 
one Thioglitazone (-` 1,742 / QALY), 27 units of insulin plus one Biguanide plus one 
Sulphonyl ureas (-` 5,186 / QALY), one Alpha Glucosidase inhibitor plus one  Biguanide 
plus two Sulphonyl ureas (-` 6,814 / QALY), 27 units of insulin plus one  Biguanide plus two 
Sulphonyl ureas (-` 7,263 / QALY), 27 units of insulin plus one Alpha Glucosidase inhibitor 
plus one  Sulphonyl ureas (-` 7,364 / QALY), one Alpha Glucosidase inhibitor plus one  
Biguanide plus one  Sulphonyl ureas (-` 8,368 / QALY), 27 units of insulin plus one  Alpha 
Glucosidase inhibitor plus two Sulphonyl ureas (-` 8,679 / QALY), one  Alpha Glucosidase 
inhibitor plus one  Biguanide plus three Sulphonyl ureas (-` 9,031 / QALY), 27 X 2 units of 
insulin plus one  Biguanide plus one  Sulphonyl ureas (-` 12,233/ QALY), 27 X 3 units of 
insulin plus one  Alpha Glucosidase inhibitor plus one  Sulphonyl ureas (-` 18,594 / QALY), 
27 X 2 units of insulin plus one  Biguanide plus two Sulphonyl ureas (-` 23,644 / QALY), 27 
units of insulin plus one  Sulphonyl ureas plus one  DPP IV inhibitor (-` 34,977 / QALY), 27 
X 3 units of insulin plus one  Biguanide plus one  DPP IV inhibitors (-` 47,525 / QALY), one  
Biguanide plus one  DPP IV inhibitor plus one  Sulphonyl ureas (-` 56,717 / QALY) and one  
Biguanide plus two DPP IV inhibitors plus one  Sulphonyl ureas (-` 62,677 / QALY). Table 
33 
In the cost effectiveness analysis of 4-drug therapy with a combination of  27 
units of  Insulin plus one Biguanide plus one DPP IV inhibitor plus one Sulphonyl ureas was 
taken as the standard as it poses a higher QALY (1.00) with a minimal annual expenditure of 
` 33,985 than others. A combination of 27 units insulin plus one Sulphonyl ureas plus one 
Alpha Glucosidase inhibitor plus one DPP IV inhibitors and 27 units insulin plus one 
Sulphonyl ureas plus one Biguanide plus one DPP IV inhibitor effectively produced the 
similar QALY with an annual discounted incremental cost of -` 2,599 and -` 4,829 
respectively, which is still a higher cost than that of the standard. The incremental cost 
effectiveness ratio of the other combinations where the  standard dominates includes were 27 
units insulin plus three Sulphonyl ureas plus  one  Thioglitazone plus one  Biguanide (` 
61,095), 27 units insulin plus three Sulphonyl ureas plus one  Alpha Glucosidase inhibitor 
plus one  Biguanide (` 48,827), one  Alpha Glucosidase inhibitor plus one  Biguanide plus 
one  Sulphonyl ureas plus  one  Thioglitazone (` 42,939), 27 units insulin plus one  Alpha 
Glucosidase inhibitor plus one  Biguanide plus two Sulphonyl ureas (` 38,331), 27 units 
insulin plus two Sulphonyl ureas plus  one  Thioglitazone plus one  Biguanide (` 31,997), 27 
units insulin plus one  Alpha Glucosidase inhibitor plus one  Sulphonyl ureas plus one  
Thioglitazone (` 26,394), 27 X 2 units insulin plus one  Alpha Glucosidase inhibitor plus one  
Biguanide plus one  Sulphonyl ureas (` 21,745), 27 X 2 units insulin plus one Alpha 
Glucosidase inhibitor plus one  Biguanide plus two Sulphonyl ureas (` 19,984), 27 X 3 units 
insulin plus one  Alpha Glucosidase inhibitor plus one  Biguanide plus one  Sulphonyl ureas 
(` 18,785), one  Alpha Glucosidase inhibitor plus one  Biguanide plus one  DPP IV inhibitor 
plus one   Sulphonyl ureas (` 2,279), 27 units insulin plus one  Biguanide plus one  DPP IV 
inhibitor plus two  Sulphonyl ureas (-` 2,021), 27 units insulin plus one  Biguanide plus two 
DPP IV inhibitors plus one Sulphonyl ureas (-` 30,545), one  Alpha Glucosidase inhibitor 
plus one  Biguanide plus 2 DPP IV inhibitors plus one  Sulphonyl ureas (-` 33,500), and 27 
units insulin plus one  Alpha Glucosidase inhibitor plus one  Biguanide plus one   Sulphonyl 
ureas (-` 1,67,786). Table 35 
Assessment of incremental cost to be spent to obtain the QALY in case of 
combination therapy was calculated taking a standard combination of one Alpha Glucosidase 
inhibitor plus one Biguanide plus one DPP IV inhibitor plus one Thioglitazone plus two 
Sulphonyl ureas as they have shown to elicit the QALY of 1.00 with an annual expenditure of 
` 32,821. The drugs showing similar QALY with an increased discounted incremental cost (-
` 5,698) spend annually was a combination of 27 units insulin plus one  Alpha Glucosidase 
inhibitor plus one  Biguanide plus one  DPP IV inhibitor plus one Sulphonyl ureas plus one  
Thioglitazone with an increased discounted incremental cost (-` 5,698). The standard 
combination dominates the ICER of the other drugs that includes 27 units insulin plus one  
Alpha Glucosidase inhibitor plus one  Biguanide plus one   Sulphonyl ureas plus one  
Thioglitazone (` 35,813), 27 units insulin plus one  Alpha Glucosidase inhibitor plus one  
Biguanide plus two Sulphonyl ureas plus one  Thioglitazone (` 22,872), one Alpha 
Glucosidase inhibitor plus one  Biguanide plus one  DPP IV inhibitor plus one   Sulphonyl 
ureas plus one  Thioglitazone (-` 976), 27 units insulin plus one  Alpha Glucosidase inhibitor 
plus one  Biguanide plus one  DPP IV inhibitor plus one   Sulphonyl ureas (-` 7,546), 27 
units insulin plus one  Alpha Glucosidase inhibitor plus one  Biguanide plus one DPP IV 
inhibitor plus one   Sulphonyl ureas plus one  Thioglitazone (-` 7,673), 27 units insulin plus 
one  Alpha Glucosidase inhibitor plus one  Biguanide plus one  DPP IV inhibitor plus two 
Sulphonyl ureas (-` 9,719), 27 X 3 units insulin plus one  Alpha Glucosidase inhibitor plus 
one  Biguanide plus one  DPP IV inhibitor plus  two Sulphonyl ureas (-` 17,294), 27 X 2 
units insulin plus one  Alpha Glucosidase inhibitor plus one  Biguanide plus one DPP IV 
inhibitor plus two Sulphonyl ureas (-` 31,068), one  Alpha Glucosidase inhibitor plus one  
Biguanide plus two DPP IV inhibitors plus three Sulphonyl ureas plus one  Thioglitazone (-` 
34,768), and 27 units insulin plus one  Alpha Glucosidase inhibitor plus one  Biguanide plus 
two DPP IV inhibitors plus two Sulphonyl ureas (-` 94,054).Table 37 
Using individual brands of drugs for combination therapy will be more economical 
than using market available combinations. By using fewer combinat ion products with 
individual drugs may help to reduce the total expenditure of Diabetes per year.  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Conclusion 
 
 
 
 
VII. CONCLUSION 
The aim of the present study was to perform pharmacoeconomic analysis of 
antidiabetic drugs in a diabetology outpatient setting. Out of a total number of 421 patients 
enrolled in this study, 407 patients were analyzed for demographic study and the cost 
minimization and cost effectiveness analysis was performed for 388 patients. The study has 
estimated the following results.  
 Males are found to be more affected by diabetes than do with females, with an 
average age in the range of 51-60 years of age and 1-5 years of duration.  
 Population within the range of 51-60 years  and 1-5 years duration was found have 
increased percentage of non-vegetarians, Obese, Sedentary, Alcoholics and tobacco 
users either as smokers or as chewers with increased weight loss.  
 Micro vascular complications such as Retinopathy, Foot ulcer, Nephropathy and 
Neuropathy was very common with patients under 51-60 years of age and 1-5 years of 
diabetes duration, whereas with 1-5 years of diabetic duration, Hypertension, 
Dyslipidemia, and Cardio vascular disease are common macro vascular complications 
with 61-70 years, 51-70 years and 51-60 years of age, but Peripheral vascular diseases 
was common with 6-10 years of duration and 51-60 years of age,  
 Suffering and Physical activity restriction was much lower with 51-60 years of age 
and 1-5 years of duration, at the same time population with 1-5 years of duration had 
a mild to moderate suffering and physical activity restriction  with 41-50 years and 
51-60 years of age respectively. Severe suffering was noticed with 11-15 years of 
duration and 71-80 years of age, while physical activity restriction was severe among 
patients with 41-50 years of age and 1-5 years of duration. 
 Increased numbers of patients were treated effectively with a combination of 2- drug 
combination therapy. 
 Single drug therapy was shown to be not advisable for treatment as it failed to posses 
the increased QALY. Sulphonyl ureas shown to provide a superior ICER than, 
Biguanides which was most commonly prescribed for single drug therapy and hold 
the lowest cost. 
 A combination of one Biguanide plus one Sulphonyl ureas was prescribed mostly for 
2- Drug combination therapy, than one Biguanide plus one Thioglitazones with 
improved ICER hold the lowest cost.  
 A higher number of patients were administered with a one Biguanide plus one 
Sulphonyl urea plus 27 units of Insulin for 3- Drug combination therapy, but the 
successful rate of ICER and lowest cost was for treatment was found with one 
Biguanide plus one Thioglitazone plus one Sulphonyl urea.  
 With 4- Drug combination therapy, a combination of one Biguanide plus one DPP IV 
inhibitor plus one Sulphonyl urea plus insulin with an average dose of 27 units/ day 
had much better ICER than those treated with one each of Alpha Glucosidase 
inhibitors, Biguanides, DPP IV inhibitors and Sulphonyl ureas which was prescribed 
for a large population, but lowest cost was used up was for one Alpha Glucosidase 
inhibitor plus one Biguanide plus one Sulphonyl urea plus one Thioglitazone. 
 Using Combination therapy with >4 drugs, 27 units of Insulin plus one Alpha 
Glucosidase inhibitor plus one Biguanide plus one DPP IV inhibitor plus one 
Sulphonyl urea was prescribed for higher group of patients, while the lowest cost of 
therapy was for one Alpha Glucosidase inhibitor plus one Biguanide plus one DPP IV 
inhibitor plus one Sulphonyl urea plus one Thioglitazone which had a less efficacy 
than the combination of one Alpha Glucosidase inhibitor plus one Biguanide plus one 
DPP IV inhibitor plus one Thioglitazones plus two Sulphonyl ureas having a 
beneficial ICER. 
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Annexure 
 
 
 
 
 
ANNEXURE I 
DATA ENTRY FORM 
Form No:                                                                                Date: 
DEMOGRAPHICS 
Patient name:  Age:  Sex: 
Diabetic duration: Smoker:  Food habits: 
Occupational situation: Existing co-morbidities:  
Active  Hypertension  
Pensioner  Dyslipidemia  
Non worker  Weight Gain/Loss  
CLINICAL DATA 
Tests Index Final Tests Index Final 
HbA1C:   BMI:    
Fasting BS:   Total cholesterol:   
Random BS:    HDL:   
Post prandial:   LDL:   
BP:    Triglycerides:   
DIABETIC COMPLICATIONS 
Micro vascular Macro vascular 
Retinopathy  Cardio VD  
Foot ulcer  Cerebral VD  
Nephropathy  Peripheral VD  
Neuropathy    
QUALITY OF LIFE HEALTH QUESTIONNAIRE 
Suffering Daily activity limitation 
None  None  
Mild  Mild  
Moderate  Moderate  
Severe  Severe  
DRUGS USED FOR TREATMENT: 
Date Drugs Dose Frequency 
    
    
    
    
    
    
    
    
 
 
 
 
  
ANNEXURE II 
HADORN & UEBERSAX’s 
 “THE QUALITY OF LIFE HEALTH QUESTIONAIRE” 
Suffering Daily Activity Limitations Ratings 
None None 1.00 
None Mild 0.89 
None Moderate 0.66 
None Severe 0.41 
Mild None 0.83 
Mild Mild 0.78 
Mild Moderate 0.60 
Mild Severe 0.39 
Moderate None 0.63 
Moderate Mild 0.61 
Moderate Moderate 0.51 
Moderate Severe 0.34 
Severe None 0.41 
Severe Mild 0.37 
Severe Moderate 0.32 
Severe Severe 0.18 
(Death) - 0.00 
 
 
 
 
